General References


Ta NN, Schuyler CA, Li Y, Lopes-Virella MF, Huang Y. DPP-4 (CD26) Inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58:157-66.

Taavitsainen P, Anttila M, Nyman L, Karnani H, Salonen JS, Pelkonen O. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol 2000; 86:215-21.

Taavitsainen P, Juvonen R, Pelkonen O. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene. Drug Metab Dispos 2001; 29:217-22.

Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56:135-40.

Tabara Y, Kohara K, Kawamoto R et al. Association of four genetic loci with uric acid levels and reduced renal function: the J-SHIPP Suita study. Am J Nephrol 2010; 32:279-86.

Tabata S, Yin G, Ogawa S, Yamaguchi K, Mineshita M, Kono S. Genetic polymorphism of cholesterol 7alpha-hydroxylase (CYP7A1) and colorectal adenomas: Self defense forces health study. Cancer Sci 2006; 97:406-10.

Tabaton M, Rolleri M, Masturzo P et al. Apolipoprotein E epsilon-4 allele frequency is not increased in progressive supranuclear palsy. Neurology 1995; 45:1764-5.

Tabb MM, Sun A, Zhou C et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J Biol Chem 2003; 278:43919-27.

Tabel Y, Berdeli A, Mir S, Serdaroğlu E, Yilmaz E. Effects of genetic polymorphisms of the renin-angiotensin system in children with nephrotic syndrome. J Renin Angiotensin Aldosterone Syst 2005; 6:138-44.

Tabernero J, Cervantes A, Rivera F et al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol 2010; 28:1181-9.

Tabet F, Lambert G, Cuesta Torres LF et al. Lipid-free apolipoprotein a-I and discoidal reconstituted high-density lipoproteins differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol 2011; 31:1192-200.

Tabolacci E, de Pascalis I, Accadia M et al. Modest reactivation of the mutant FMR1 gene by valproic acid is accompanied by histone modifications but not DNA demethylation. Pharmacogenet Genomics 2008; 18:738-41.

Tabor MH, Clay MR, Owen JH et al. Head and neck cancer stem cells: the side population. Laryngoscope 2011; 121:527-33.

Tachibana S, Fujimaki Y, Yokoyama H, Okazaki O, Sudo K. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3. 5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions. Drug Metab Dispos 2005; 33:1628-36.

Tachibana S, Tanaka M, Fujimaki Y et al. Metabolism of the calmodulin antagonist DY-9760e in animals and humans. Xenobiotica 2005; 35:499-517.

Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 2009; 39:430-43.

Tadić A, Rujescu D, Müller MJ et al. A monoamine oxidase B gene variant and short-term antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1370-7.

Tadin-Strapps M, Peterson LB, Cumiskey AM et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 2011; 52:1084-97.

Taegtmeyer AB, Breen JB, Smith J et al. ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. Transplantation 2010; 89:75-82.

Taegtmeyer AB, Breen JB, Smith J et al. Effect of ABCB1 genotype on pre- and post-cardiac transplantation plasma lipid concentrations. J Cardiovasc Transl Res 2011; 4:304-12.

Taesotikul T, Dumrongsakulchai W, Wattanachai N et al. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab Pharmacokinet 2011; 26:154-61.

Tafoya LC, Mameli M, Miyashita T, Guzowski JF, Valenzuela CF, Wilson MC. Expression and function of SNAP-25 as a universal SNARE component in GABAergic neurons. J Neurosci 2006; 26:7826-38.

Tafreshi MJ, Zagnoni LG, Gentry EJ. Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma? Pharmacotherapy 2006; 26:388-94.

Tagen M, Zhuang Y, Zhang F et al. P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice. Drug Metab Lett 2010; 4:195-201.

Taghizadeh R, Noh M, Huh YH et al. CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells. PLoS One 2010. doi:10. 1371/journal. pone. 0015183.

Tagliavini F, Lievens PMJ, Tranchant C et al. A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J Biol Chem 2001; 276:6009-15.

Tagliavini F, Prelli F, Ghiso J et al. Amyloid fibrils in Gerstmann-Straussler-Schein disease (Indian and Swedish kindreads) express only PrP peptides encoded by the mutant allele. Cell 1994; 79:695-703.

Taguchi M, Imaoka S, Yoshii K et al. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes. Res Commun Mol Pathol Pharmacol 2001; 109:53-63.

Taguchi M, Nozawa T, Kameyama T et al. Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. Eur J Clin Pharmacol 2003; 59:385-8.

Taguchi M, Nozawa T, Mizumaki K et al. Nonlinear mixed effects model analysis of the pharmacokinetics of metoprolol in routinely treated Japanese patients. Biol Pharm Bull 2004; 27:1642-8.

Tahara T, Shibata T, Nakamura M et al. Association between polymorphisms in the XRCC1 and GST genes, and CpG island methylation status in colonic mucosa in ulcerative colitis. Virchows Arch 2011; 458:205-11.

Tahara T, Shibata T, Nakamura M et al. Effect of IL-1β and TNF-α polymorphisms on the prognosis and survival of gastric cancer patients. Clin Exp Med 2011. doi:10. 1007/s10238-010-0129-y.

Tahara T, Shibata T, Yamashita H, Hirata I, Arisawa T. Influence of MDR1 polymorphism on H. pylori-related chronic gastritis. Dig Dis Sci 2011; 56:103-8.

Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010; 9:34-40.

Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009; 26:249-62.

Tai ES, Demissie S, Cupples LA et al. Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2002; 22:805-10.

Tai J, Yang M, Ni X et al. Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. Cancer Genet Cytogenet 2010; 196:76-82.

Tain LS, Mortiboys H, Tao RN, Ziviani E, Bandmann O, Whitworth AJ. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci 2009; 12:1129-35.

Taipalensuu J, Törnblom H, Lindberg G et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001; 299:164-70.

Tak E, Lee S, Lee J et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells. J Hepatol 2011; 54:328-39.

Takabe K, Kim RH, Allegood JC et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem 2010; 285:10477-86.

Takada K, Arefayene M, Desta Z et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50:2202-10.

Takada K, Imamura N, Gustafson KR, Henrich CJ. Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter. Bioorg Med Chem Lett 2010; 20:1330-3.

Takada M, Saji S, Masuda N et al. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast 2011. doi:10. 1016/j. breast. 2011. 07. 015.

Takada T, Ogino M, Miyata M, Shimada M, Nagata K, Yamazoe Y. Differences in transactivation between rat CYP3A1 and human CYP3A4 genes by human pregnane X receptor. Drug Metab Pharmacokinet 2004; 19:103-13.

Takada Y, Ray N, Ikeda E et al. Fos proteins suppress dextran sulfate sodium-induced colitis through inhibition of NF-kappaB. J Immunol 2010; 184:1014-21.

Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 2008; 283:9674-80.

Takahashi E, Fujita K, Kamataki T, Arimoto-Kobayashi S, Okamoto K, Negishi T. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin. Mutat Res 2002; 508:147-56.

Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40:587-603.

Takahashi H, Fujii T, Inoue Y et al. A case of breast meningeal carcinomatosis caused by trastuzumab treatment as adjuvant chemotherapy. Gan To Kagaku Ryoho 2010; 37:1607-9.

Takahashi H, Ieiri I, Wilkinson GR et al. 5’-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103:3055-7.

Takahashi H, Wilkinson GR, Nutescu EA et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance does of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16:101-10.

Takahashi K, Adachi K, Kunimoto S, Wakita H, Takeda K, Watanabe A. Potent inhibitors of amyloid β fibrillization, 4,5-dianilinophthalimide and staurosporine aglycone, enhance degradation of preformed aggregates of mutant Notch3. Biochem Biophys Res Commun 2010; 402:54-8.

Takahashi K, Uejima E, Morisaki T, Takahashi K, Kurokawa N, Azuma J. In vitro inhibitory effects of Kampo medicines on metabolic reactions catalyzed by human liver microsomes. J Clin Pharm Ther 2003; 28:319-27.

Takahashi K, Yano I, Fukuhara Y et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab Pharmacokinet 2007; 22:441-4.

Takahashi M, Kimura A. HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves’ disease. J Hum Genet 2010; 55:323-6.

Takahashi M, Sakurai M, Enosawa S, Omasa T, Tsuruoka S, Matsumura T. Double-compartment cell culture apparatus: construction and biochemical evaluation for bioartificial liver support. Cell Transplant 2006; 15:945-52.

Takahashi M, Washio T, Suzuki N, Igeta K, Yamashita S. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 2009; 98:4343-53.

Takahashi N, Miura M, Scott SA et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010; 55:731-7.

Takahashi N, Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology 2011; 87:241-8.

Takahashi N, Murakami H, Kodama K et al. Association of a polymorphism at the 5’-region of the angiotensin II type 1 receptor with hypertension. Ann Hum Genet 2000; 64:197-205.

Takahashi S. RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL). Clin Calcium 2011; 21:1239-47.

Takahashi S, Ushida M, Komine R et al. Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2008; 121:509-17.

Takahashi T, Kaku T, Sato T, Watanabe K, Sato J. Effects of Acanthopanax senticosus HARMS extract on drug transport in human intestinal cell line Caco-2. J Nat Med 2010; 64:55-62.

Takahashi T, Tabuchi T, Tamaki Y, Kosaka K, Takikawa Y, Satoh T. Carnosic acid and carnosol inhibit adipocyte differentiation in mouse 3T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism. Biochem Biophys Res Commun 2009; 382:549-54.

Takahashi T, Takahashi K, Yamashina M et al. Association of the TNF-{alpha}-C-857T polymorphism with resistance to the cholesterol-lowering effect of HMG-CoA reductase inhibitors in type 2 diabetic subjects. Diabetes Care 2010; 33:463-6.

Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capsaicin after cilazapril usage. Respir Med 2001; 95:130-5.

Takahashi Y, Endo Y, Sugiyama Y et al. XPA gene mutations resulting in subtle truncation of protein in xeroderma pigmentosum group A patients with mild skin symptoms. J Invest Dermatol 2010; 130:2481-8.

Takahashi Y, Hayashi I, Tominari Y et al. Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003; 278:18664-70.

Takahashi Y, Shirono H, Arisaka O et al. Biologically inactive growth hormone caused by an amino acid substitution. J Clin Invest 1997; 100:1159-65.

Takahata T, Ookawa K, Suto K et al. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines. Basic Clin Pharmacol Toxicol 2008; 102:399-407.

Takaki Y, Iwata N, Tsubuki S et al. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain. J Biochem 2000; 128:897-902.

Takaku T, Mikata K, Matsui M, Nishioka K, Isobe N, Kaneko H. In vitro metabolism of trans-permethrin and its major metabolites, PBalc and PBacid, in humans. J Agric Food Chem 2011; 59:5001-5.

Takakura Y, Hinoi T, Oue N et al. CDX2 regulates multidrug resistance 1 gene expression in malignant intestinal epithelium. Cancer Res 2010; 70:6767-78.

Takakuwa O, Oguri T, Ozasa H et al. Over-expression of MDR1 in amrubicinol-resistant lung cancer cells. Cancer Chemother Pharmacol 2011; 68:669-76.

Takamiya O, Hino K. A patient homozygous for a Gly354Cys mutation in factor VII that results in severely impaired secretion of the molecule, but not complete deficiency. Br J Haematol 2004; 124:336-42.

Takamura T, Harama D, Fukumoto S et al. Lactobacillus bulgaricus OLL1181 activates the aryl hydrocarbon receptor pathway and inhibits colitis. Immunol Cell Biol 2011; 89:817-22.

Takanaga H, Ohnishi A, Matsuo H et al. Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model. Br J Clin Pharmacol 2000; 49:49-58.

Takanaga H, Ohnishi A, Yamada S et al. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther 2000; 293:230-6.

Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10:95-104.

Takane H, Miyata M, Burioka N et al. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. J Hum Genet 2006; 51:822-6.

Takano A, Uchiyama M, Kajimura N et al. A missense variation in human casein kinase I epsilon gene that induces functional alteration and shows an inverse association with circadian rhythm sleep disorders. Neuropsychopharmacology 2004; 29:1901-9.

Takano Y, Iwata H, Yano Y et al. Up-regulation of connexin 32 gene by 5-aza-2’-deoxycytidine enhances vinblastine-induced cytotoxicity in human renal carcinoma cells via the activation of JNK signalling. Biochem Pharmacol 2010; 80:463-70.

Takanohashi T, Isaka M, Ubukata K, Mihara R, Bernard BK. Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol 2010; 29(2 Suppl):22-6.

Takanohashi T, Koizumi T, Mihara R, Okudaira K. Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies. Drug Metab Pharmacokinet 2007; 22:409-18.

Takanohashi T, Kubo S, Nakayama A, Mihara R, Hayashi M. Inhibition of human liver microsomal CYP by nateglinide. J Pharm Pharmacol 2010; 62:592-7.

Takara K, Hayashi R, Kokufu M et al. Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. Drug Chem Toxicol 2009; 32:332-7.

Takara K, Kitada N, Yoshikawa E et al. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett 2009; 278:88-96.

Takara K, Sakaeda T, Kakumoto M et al. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res 2009; 17:527-33.

Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis 2006; 9:309-17.

Takashima T, Nagata H, Nakae T et al. Positron emission tomography studies using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester for the evaluation of hepatobiliary transport. J Pharmacol Exp Ther 2010; 335:314-23.

Takatori R, Takahashi KA, Tokunaga D et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin Exp Rheumatol 2006; 24:546-54.

Takeba Y, Matsumoto N, Takenoshita-Nakaya S et al. Comparative study of culture conditions for maintaining CYP3A4 and ATP-binding cassette transporters activity in primary cultured human hepatocytes. J Pharmacol Sci 2011; 115:516-24.

Takeda M, Khamdang S, Narikawa S et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002; 302:666-71.

Takeda M, Yamashita T, Sasaki N et al. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler Thromb Vasc Biol 2010; 30:2495-503.

Takeda S, Ishii Y, Iwanaga M et al. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol 2005; 67:665-72.

Takeda S, Ishii Y, Iwanaga M et al. Interaction of cytochrome P450 3A4 and UDP-glucuronosyltransferase 2B7: evidence for protein-protein association and possible involvement of CYP3A4 J-helix in the interaction. Mol Pharmacol 2009; 75:956-64.

Takeda S, Ishii Y, Mackenzie PI et al. Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull 2005; 28:2026-7.

Takehara A, Kawakami K, Ohta N et al. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer. Anticancer Res 2005; 6:4455-61.

Takehashi M, Alioto T, Stedeford T et al. Septin 3 gene polymorphism in Alzheimer’s disease. Gene Expr 2004; 11:263-70.

Takekuma Y, Takenaka T, Kiyokawa M et al. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. Biol Pharm Bull 2007; 30:537-42.

Takekuma Y, Takenaka T, Yamazaki K, Ueno K, Sugawara M. Stereoselective metabolism of racemic carvedilol by UGT1A1 and UGT2B7, and effects of mutation of these enzymes on glucuronidation activity. Biol Pharm Bull 2007; 30:2146-53.

Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. Selective inhibition of methoxyflavonoids on human CYP1B1 activity. Bioorg Med Chem 2010; 18:6310-5.

Takemura H, Uchiyama H, Ohura T et al. A methoxyflavonoid, chrysoeriol, selectively inhibits the formation of a carcinogenic estrogen metabolite in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2010; 118:70-6.

Takemura Y, Ouchi N, Shibata R et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. J Clin Invest 2007; 117:375-86.

Takeshita A, Koibuchi N, Oka J, Taguchi M, Shishiba Y, Ozawa Y. Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur J Endocrinol 2001; 145:513-7.

Takeshita A, Taguchi M, Koibuchi N, Ozawa Y. Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem 2002; 277:32453-8.

Takeshita H, Tsubota E, Takatsuka H, Kunito T, Fujihara J. Cytochrome P450 2J2*7 polymorphisms in Japanese, Mongolians and Ovambos. Cell Biochem Funct 2008; 26:813-6.

Takeshita M, Miura M, Ohkubo T, Sugawara K. Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol. Enantiomer 2000; 5:189-95.

Takeshita T, Mao XQ, Morimoto K. The contribution of polymorphism in the alcohol dehydrogenase beta subunit to alcohol sensitivity in a Japanese population. Hum Genet 1996; 97:409-13.

Taketo M, Yokoyama S, Rochelle J et al. Mouse B2 bradykinin receptor gene maps to distal chromosome 12. Genomics 1995; 27:222-3.

Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009. doi:10. 1371/journal. pgen. 1000433.

Takeuchi H, Saoo K, Matsuda Y et al. 8-Methoxypsoralen, a potent human CYP2A6 inhibitor, inhibits lung adenocarcinoma development induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice. Mol Med Report 2009; 2:585-8.

Takeuchi Y, Fujino Y, Fukushima K et al. Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses. J Vet Pharmacol Ther 2011. doi:10. 1111/j. 1365-2885. 2011. 01296. x.

Takeyama Y, Kanegae K, Inomata S et al. Sustained upregulation of sodium taurocholate cotransporting polypeptide and bile salt export pump and downregulation of cholesterol 7α-hydroxylase in the liver of patients with end-stage primary biliary cirrhosis. Med Mol Morphol 2010; 43:134-8.

Takigawa N, Tanimoto M. Vinca alkaloid and MDR1. Gan To Kagaku Ryoho 2008; 35:1086-9.

Takiguchi T, Tomita M, Matsunaga N, Nakagawa H, Koyanagi S, Ohdo S. Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells. Pharmacogenet Genomics 2007; 17:1047-56.

Takiue Y, Hosoyamada M, Kimura M, Saito H. The effect of female hormones upon urate transport systems in the mouse kidney. Nucleosides Nucleotides Nucleic Acids 2011; 30:113-9.

Takizawa D, Kakizaki S, Horiguchi N et al. Histone deacetylase inhibitors induce cytochrome P450 2B by activating nuclear receptor constitutive androstane receptor. Drug Metab Dispos 2010; 38:1493-8.

Takizawa M, Kawakami K, Obata T et al. In vitro sensitivity to platinum-derived drugs is associated with expression of thymidylate synthase and dihydropyrimidine dehydrogenase in human lung cancer. Oncol Rep 2006; 15:1533-9.

Takizawa Y, Kishimoto H, Kitazato T, Tomita M, Hayashi M. Changes in the localization of ileal p-glycoprotein induced by intestinal ischemia/reperfusion. Biol Pharm Bull 2011; 34:408-14.

Talakad JC, Shah MB, Walker GS, Xiang C, Halpert JR, Dalvie D. Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab Dispos 2011; 39:539-50.

Talar-Wojnarowska R, Gasiorowska A, Smolarz B et al. Comparative evaluation of p53 mutation in pancreatic adenocarcinoma and chronic pancreatitis. Hepatogastroenterology 2006; 53:608-12.

Talbert RL. Safety issues with statin therapy. J Am Pharm Assoc 2006; 46:479-88.

Talbot C, Lendon C, Craddock N et al. Protection against Alzheimer’s disease with apoE epsilon-2. Lancet 1994; 343:1432-3.

Taléns-Visconti R, Bonora A, Jover R et al. Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J Gastroenterol 2006; 12:5834-45.

Talkowski ME, Bamne M, Mansour H, Nimgaonkar VL. Dopamine genes and schizophrenia: case closed or evidence pending? Schizophr Bull 2007; 33:1071-81.

Talmon T, Scharf J, Mayer E, Lanir N, Miller B, Brenner B. Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations. Am J Ophthalmol 1997; 124:689-91.

Talmud PJ, Drenos F, Shah S et al. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet 2009; 85:628-42.

Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-41.

Tall AR. The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 2009; 104(10 Suppl):39-45.

Tamaki H, Satoh H, Hori S, Ohtani H, Sawada Y. Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure-inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 2010; 25:170-9.

Tamaki S, Nakamura Y, Tabara Y et al. Relationship between metabolic syndrome and Trp64arg polymorphism of the beta-adrenergic receptor gene in a general sample: the Shigaraki study. Hypertens Res 2006; 29:891-6.

Tamaki S, Nakamura Y, Tabara Y et al. Association between polymorphism of the AGTR1 and cardiovascular events in a Japanese general sample (The Shigaraki Study). Int J Cardiol 2009; 136:354-5.

Tamaki Y, Arai T, Sugimura H et al. Association between cancer risk and drug metabolizing enzyme gene (CYP2A6, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in Japanese cases of lung cancer. Drug Metab Pharmacokinet 2011. doi:10. 2133/dmpk. DMPK-11-RG-046.

Tamary H, Fromovich Y, Shalmon L et al. Ala244Val is a common, probably ancient mutation causing factor VII deficiency in Moroccan and Iranian Jews. Thromb Haemost 1996; 76:283-91.

Tamez S, Norizoe C, Ochiai K et al. Vitamin D receptor polymorphisms and prognosis of patients with epithelial ovarian cancer. Br J Cancer 2009; 101:1957-60.

Tamm ER. Development of the iridocorneal angle and congenital glaucoma. Ophthalmologe 2011; 108:610-7.

Tamminga WJ, Wemer J, Oosterhuis B et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999; 55:177-84.

Tamminga WJ, Wemer J, Oosterhuis B, de Zeeuw RA, de Leij LF, Jonkman JH. The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers. Eur J Clin Pharmacol 2001; 57:717-22.

Tamori A, Shinzaki M, Kosaka S et al. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int 2007; 1:95-100.

Tamura H, Kohchi C, Yamada R et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res 1991; 19:69-75.

Tamura K, Furihata M, Tsunoda T et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67:5117-25.

Tamura K, Nakajima S, Hirota Y et al. Genetic association of a polymorphism of the cAMP-responsive element binding protein-binding protein with steroid-induced osteonecrosis after kidney transplantation. J Bone Miner Metab 2007; 25:320-5.

Tamura T, Kurata M, Inoue S et al. Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping. Nagoya J Med Sci 2011; 73:25-31.

Tan AR, Dowlati A, Jones SF et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist 2010; 15:1253-61.

Tan BB, Li Y, Han J et al. Relationship of cyclooxygenase-2 and multidrug resistance associated factors to chemosensitivities in gastrointestinal carcinomas. Sichuan Da Xue Xue Bao Yi Xue Ban 2010; 41:128-31.

Tan H, Wang Q, Wang A et al. Influence of GSTs, CYP2E1 and mEH polymorphisms on 1, 3-butadiene-induced micronucleus frequency in Chinese workers. Toxicol Appl Pharmacol 2010; 247:198-203.

Tan HL, Kupershmidt S, Zhang R et al. Brugada syndrome with marked conduction disease: dual implications of a SCN5A mutation. Pacing Clin Electrophysiol 2008; 5:630-4.

Tan HY, Callicott JH, Weinberger DR. Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia. Cereb Cortex 2007; 17 Suppl 1:171-81.

Tan J, Town T, Paris D et al. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999; 286:2352-5.

Tan J, Town T, Suo Z et al. Induction of CD40 on human endothelial cells by Alzheimer’s beta-amyloid peptides. Brain Res Bull 1999; 50:143-8.

Tan KP, Wang B, Yang M et al. Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2). Mol Pharmacol 2010; 78:175-85.

Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010; 112:320-3.

Tan SH, Lee SC, Goh BC, Wong J. Pharmacogenetics in breast cancer therapy. Clin Cancer Res 2008; 14:8027-41.

Tan SY. FcgammaRIIa polymorphism in systemic lupus erythematosus. Kidney Blood Press Res 2000; 23:138-42.

Tan X, Yim SY, Uppu P, Kleinow KM. Enhanced bioaccumulation of dietary contaminants in catfish with exposure to the waterborne surfactant linear alkylbenzene sulfonate. Aquat Toxicol 2010; 99:300-8.

Tanabe T, Fukusaki M, Terao Y et al. Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation. J Anesth 2008; 22:70-3.

Tanahashi H, Asada T, Tabira T. Association between tau polymorphism and male early-onset Alzheimer’s disease. Neuroreport 2004; 15:175-9.

Tanaka A, Nagamatsu T, Yamaguchi M et al. Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother 2011; 45:1.

Tanaka AR, Abe-Dohmae S, Ohnishi T et al. Effects of mutations of ABCA1 in the first extracellular domain on subcellular trafficking and ATP binding/hydrolysis. J Biol Chem 2003; 278:8815-9.

Tanaka C, Yin OQ, Smith T et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011; 51:75-83.

Tanaka E. In vivo age-related changes in hepatic drug-oxidizing capacity in humans. J Clin Pharm Ther 1998; 23:247-55.

Tanaka E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J Clin Pharm Ther 1999; 24:87-92.

Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999; 24:339-46.

Tanaka E. Clinically significant pharmacokinetic drug interactions with benzodiazepines. J Clin Pharm Ther 1999; 24:347-55.

Tanaka E, Kurata N, Yasuhara H. Involvement of cytochrome P450 2C9, 2E1 and 3A4 in trimethadione N-demethylation in human microsomes. J Clin Pharm Ther 2003; 28:493-6.

Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants – an update. J Clin Pharm Ther 1998; 23:331-6.

Tanaka E, Nakamura T, Inomata S, Honda K. Effects of premedication medicines on the formation of the CYP3A4-dependent metabolite of ropivacaine, 2’, 6’-Pipecoloxylidide, on human liver microsomes in vitro. Basic Clin Pharmacol Toxicol 2006; 98:181-3.

Tanaka E, Narisawa C, Nakamura H et al. Changes in the enzymatic activities of beagle liver during maturation as assessed both in vitro and in vivo. Xenobiotica 1998; 28:795-802.

Tanaka F, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y, Omata M. Polymorphism of alcohol-metabolizing genes affects drinking behavior and alcoholic liver disease in Japanese men. Alcohol Clin Exp Res 1997; 21:596-601.

Tanaka H, Shimaya A, Kiso T, Kuramochi T, Shimokawa T, Shibasaki M. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci 2011; 88:559-63.

Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D. Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116:5325-35.

Tanaka M, Kobayashi D, Murakami Y et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11:261-7.

Tanaka M, Machida Y, Niu S et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004; 10:148-54.

Tanaka M, Okazaki T, Suzuki H, Abbruzzese JL, Li D. Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome. Cancer 2011; 117:744-51.

Tanaka N, Abe-Dohmae S, Iwamoto N, Fitzgerald ML, Yokoyama S. Helical apolipoproteins of high-density lipoprotein enhance phagocytosis by stabilizing ATP-binding cassette transporter A7. J Lipid Res 2010; 51:2591-9.

Tanaka N, Abe-Dohmae S, Iwamoto N, Yokoyama S. Roles of ATP-binding cassette transporter A7 in cholesterol homeostasis and host defense system. J Atheroscler Thromb 2011; 18:274-81.

Tanaka S, Kobayashi T, Nakanishi K et al. Association of HLA-DQ genotype in autoantibody-negative and rapid-onset type 1 diabetes. Diabetes Care 2002; 25:2302-7.

Tanaka S, Nohara T, Iwamoto M et al. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2009; 64:341-6.

Tanaka T, Okuda T, Yamamoto Y. Characterization of the CYP3A4 active site by homology modeling. Chem Pharm Bull 2004; 52:830-5.

Tanaka T, Scheet P, Giusti B et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet 2009; 84:477-82.

Tanaka T, Tanimoto K, Otani K et al. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer 2004; 111:617-26.

Tandon M, O’Donnell MM, Porte A et al. The design and preparation of metabolically protected new arylpiperazine 5-HT1A ligands. Bioorg Med Chem Lett 2004; 14:1709-12.

Tandy S, Chung RW, Kamili A et al. Hydrogenated phosphatidylcholine supplementation reduces hepatic lipid levels in mice fed a high-fat diet. Atherosclerosis 2010; 213:142-7.

Taneichi K, Watanabe I, Sakai I, Shibaki H. Association of immunomodulators and HLA antigens in rheumatoid arthritis. Ryumachi 1989; 29:358-64.

Tang B, Hu W, Hao J, Zhu Z. Developmental expression of steroidogenic factor-1, cyp19a1a and cyp19a1b from common carp (Cyprinus carpio). Gen Comp Endocrinol 2010; 167:408-16.

Tang C, Fang Y, Booth-Genthe C et al. Diclofenac hydroxylation in monkeys: efficiency, regioselectivity, and response to inhibitors. Biochem Pharmacol 2007; 73:880-90.

Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 2000; 293:453-9.

Tang C, Shou M, Rushmore TH, Mei Q et al. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics 2001; 11:223-35.

Tang J, Amin Usmani K, Hodgson E, Rose RL. In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam. Chem Biol Interact 2004; 147:319-29.

Tang J, Cao Y, Rose RL et al. Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. Drug Metab Dispos 2001; 29:1201-4.

Tang J, Cao Y, Rose RL, Hodgson E. In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. Chem Biol Interact 2002; 141:229-41.

Tang J, Ghosh A. Treating transgenic Alzheimer mice with a β-secretase inhibitor, what have we learned? Aging 2011; 3:14-6.

Tang J, Rivers C, Karita E et al. Allelic variants of human beta-chemokine receptor 5 (CCR5) promoter: evolutionary relationships and predictable associations with HIV-1 disease progression. Genes Immun 1999; 1:20-7.

Tang J, Zhou X, Ji H, Zhu D, Wu L. Effects of Ephedra water decoction and cough tablets containing Ephedra and Liquorice on CYP1A2 and the pharmacokinetics of Theophylline in rats. Phytother Res 2011. doi:10. 1002/ptr. 3565.

Tang JC, Zhang JN, Wu YT, Li ZX. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv. ) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res 2006; 20:1046-51.

Tang K, Li X, Xing Q et al. Genetic polymorphism analysis of cytochrome P4502E1 (CYP2E1) in Chinese Han populations from four different geographic areas of Mainland China. Genomics 2010; 95:224-9.

Tang K, Li Y, Zhang Z et al. The PstI/RsaI and DraI polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies. BMC Cancer 2010; 10:575.

Tang K, Ngoi SM, Gwee PC et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12:437-50.

Tang K, Wong LP, Lee EJD, Chong SS, Lee CGL. Genomic evidence for recent positive selection at the human MDR1 gene locus. Hum Molec Genet 2004; 13:783-97.

Tang KS, Lee CM, Teng HC, Huang MJ, Huang CS. UDP-glucuronosyltransferase 1A7 polymorphisms are associated with liver cirrhosis. Biochem Biophys Res Commun 2008; 366:643-8.

Tang L, Yao S, Till C et al. Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the prostate cancer prevention trial. Carcinogenesis 2011; 32:1500-6.

Tang L, Ye L, Lv C, Zheng Z, Gong Y, Liu Z. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol Lett 2011; 202:47-54.

Tang MX, Maestre G, Tsai WY et al. Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. Am J Hum Genet 1996; 58:574-84.

Tang SC, Lagas JS, Lankheet NA et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 2011. doi:10. 1002/ijc. 26000.

Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington’s disease mouse model. J Neurosci 2009; 29:1257-66.

Tang TT, Yang F, Chen BS et al. Dysbindin regulates hippocampal LTP by controlling NMDA receptor surface expression. Proc Natl Acad Sci USA 2009; 106:21395-400.

Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr Drug Metab 2003; 4:319-29.

Tang W, Apostol G, Schreiner PJ, Jacobs DR Jr, Boerwinkle E, Fornage M. Associations of lipoprotein lipase gene polymorphisms with longitudinal plasma lipid trends in young adults: The Coronary Artery Risk Development in Young Adults (CARDIA) study. Circ Cardiovasc Genet 2010; 3:179-86.

Tang W, Norlin M, Wikvall K. Regulation of human CYP27A1 by estrogens and androgens in HepG2 and prostate cells. Arch Biochem Biophys 2007; 462:13-20.

Tang W, Norlin M, Wikvall K. Glucocorticoid receptor-mediated upregulation of human CYP27A1, a potential anti-atherogenic enzyme. Biochim Biophys Acta 2008; 1781:718-23.

Tang W, Stearns RA, Wang RW, Chiu SH, Baillie TA. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 1999; 12:192-9.

Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2001; 2:185-98.

Tang WH, Vagelos RH, Yee YG, Fowler MB. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure. Am Heart J 2004; 148:889-94.

Tang XN, Wu J, Sun WB. Effect of longterm lower Porphyromonas gingivalis infection on the progression of atherosclerosis in apolipoprotein E-knocked out mice. Zhonghua Kou Qiang Yi Xue Za Zhi 2011; 46:75-8.

Tang Y, Lei T, Manchanda R et al. Simultaneous delivery of chemotherapeutic and thermal-optical agents to cancer cells by a polymeric (PLGA) nanocarrier: an in vitro study. Pharm Res 2010; 27:2242-53.

Tang Y, Scheef EA, Gurel Z, Sorenson CM, Jefcoate CR, Sheibani N. CYP1B1 and endothelial nitric oxide synthase combine to sustain proangiogenic functions of endothelial cells under hyperoxic stress. Am J Physiol Cell Physiol 2010; 298:665-78.

Tang YM, Green BL, Chen GF et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10:761-6.

Tang YZ, Li DQ, Sun FJ, Li L, Yu DM. P-glycoprotein regulating biphasic insulin secretion in rat pancreatic beta cells. Chin Med J 2009; 122:2587-92.

Tängemo C, Weber D, Theiss S, Mengel E, Runz H. Niemann-Pick Type C disease: characterizing lipid levels in patients with variant lysosomal cholesterol storage. J Lipid Res 2011; 52:813-25.

Tangjarukij C, Navasumrit P, Zelikoff JT, Ruchirawat M. The effects of pyridoxine deficiency and supplementation on hematological profiles, lymphocyte function, and hepatic cytochrome P450 in B6C3F1 mice. J Immunotoxicol 2009; 6:147-60.

Tani S, Nagao K, Kawamorita T, Hirayama A. Association of the serum apolipoprotein levels with the occurrence of coronary vasospasm. Coron Artery Dis 2011; 22:125-30.

Tani Y, Yamamoto H, Kawaji A et al. Hepatic cytochrome P450 and flavin-containing monooxygenase in male Nts: Mini rat, a transgenic rat carrying antisense RNA transgene for rat growth hormone. Toxicol Lett 1999; 106:159-69.

Taniguchi A, Urano W, Tanaka E et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007; 17:383-90.

Taniguchi A, Wada K, Ohno M. Development of novel culture system using nano-biotechnology. Yakugaku Zasshi 2010; 130:529-35.

Taniguchi K, Kakinuma S, Tokairin Y et al. Mild inflammation accelerates colon carcinogenesis in Mlh1-deficient mice. Oncology 2006; 71:124-30.

Taniguchi K, Wada M, Kohno K et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 1996; 56:4124-9.

Taniguchi R, Kumai T, Matsumoto N et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 2005; 97:83-90.

Taniguchi T, Doe N, Matsuyama S et al. Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation. FEBS Lett 2005; 579:5704-12.

Tanii H, Shitara Y, Horie T. Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women. Eur J Clin Pharmacol 2011; 67:1017-25.

Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004; 75:298-309.

Tanriverdi H, Kaftan HA, Evrengul H, Dursunoglu D, Turgut G, Kiliç M. QT dispersion and left ventricular hypertrophy in athletes: relationship with angiotensin-converting enzyme I/D polymorphism. Acta Cardiol 2005; 60:387-93.

Tansley GH, Burgess BL, Bryan MT et al. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J Lipid Res 2007; 48:1022-34.

Tantisira K. Genetic variation in FCER2: implications for children with asthma. Pharmacogenomics 2008; 9:805-7.

Tantisira KG, Drazen JM. Genetics and pharmacogenetics of the leukotriene pathway. J Allergy Clin Immunol 2009; 124:422-7.

Tantisira KG, Lake S, Silverman ES et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13:1353-9.

Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 2009; 19:244-7.

Tantisira KG, Silverman ES, Mariani TJ et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120:1285-91.

Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005; 14:1671-7.

Tantry US, Bliden KP, Wei C et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet 2010; 3:556-66.

Tanus-Santos JE, Desai M, Deak LR et al. Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol. Pharmacogenetics 2002; 12:407-13.

Tanwar M, Dada T, Dada R. Axenfeld-Rieger syndrome associated with congenital glaucoma and cytochrome P4501B1 gene mutations. Case Report Med 2010. doi:10. 1155/2010/212656.

Tanwar M, Dada T, Sihota R, Dada R. Identification of four novel cytochrome P4501B1 mutations (p. I94X, p. H279D, p. Q340H, and p. K433K) in primary congenital glaucoma patients. Mol Vis 2009; 15:2926-37.

Tanwar M, Kumar M, Dada T, Sihota R, Dada R. MYOC and FOXC1 gene analysis in primary congenital glaucoma. Mol Vis 2010; 16:1996-2006.

Tanwar M, Sihota R, Dada T et al. Sturge-Weber syndrome with congenital glaucoma and cytochrome P450 (CYP1B1) gene mutations. J Glaucoma 2010; 19:398-404.

Tan-Wong SM, French JD, Proudfoot NJ, Brown MA. Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene. Proc Nat Acad Sci USA 2008; 105:5160-5.

Tanzi RE, Vaula G, Romano DM et al. Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet 1992; 51:273-82.

Tao HM, Chen GZ, Lu XD, Chen GP, Shao B. TGF-β1 869T/C polymorphism and ischemic stroke: sex difference in Chinese. Can J Neurol Sci 2010; 37:803-7.

Tao L, Xiang YB, Chan KK et al. Cytochrome P4501A2 phenotype and bladder cancer risk: The Shanghai bladder cancer study. Int J Cancer 2011. doi:10. 1002/ijc. 26121.

Tao L, Xiang YB, Wang R et al. Environmental tobacco smoke in relation to bladder cancer risk-the Shanghai bladder cancer study [corrected]. Cancer Epidemiol Biomarkers Prev 2010; 19:3087-95.

Tao LY, Liang YJ, Wang F et al. Cediranib (recentin, AZD2171) reverses ABCB1-and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 2009; 64:961-9.

Tao MH, Liu JW, Lamonte MJ et al. Different associations of apolipoprotein E polymorphism with metabolic syndrome by sex in an elderly Chinese population. Metabolism 2011; 60:1488-96.

Tapaninen T, Backman JT, Kurkinen KJ, Neuvonen PJ, Niemi M. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 2011; 51:359-67.

Tapaninen T, Neuvonen PJ, Niemi M. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010; 66:497-502.

Tapaninen T, Neuvonen PJ, Niemi M. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010; 66:865-70.

Tapaninen T, Neuvonen PJ, Niemi M. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol 2011; 71:718-26.

Tapper W, Hammond V, Gerty S et al. The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 2008; 10:108.

Tarantino G, Di Minno MN, Capone D. Drug-induced liver injury: Is it somehow foreseeable? World J Gastroenterol 2009; 15:2817-33.

Tarantino P, de Marco EV, Annesi G et al. Lack of association between G-protein coupled receptor kinase 5 gene and Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 2011; 156:104-7.

Tarantino-Hutchison LM, Sorrentino C, Nadas A et al. Genetic determinants of sensitivity to beryllium in mice. J Immunotoxicol 2009; 6:130-5.

Tarasov AI, Nicolson TJ, Riveline JP et al. A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K+ channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults. Diabetes 2008; 57:1595-604.

Taratuto AL, Piccardo P, Reich EG et al. Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease. Neurology 2002; 58:362-7.

Tarazi FI, Zhang K, Baldessarini RJ. Dopamine D4 receptors: beyond schizophrenia. J Recept Signal Transduct Res 2004; 24:131-47.

Tarling EJ, Bojanic DD, Tangirala RK et al. Impaired development of atherosclerosis in Abcg1-/- Apoe-/- mice: identification of specific oxysterols that both accumulate in Abcg1-/- Apoe-/- tissues and induce apoptosis. Arterioscler Thromb Vasc Biol 2010; 30:1174-80.

Tarn AC, von Schnakenburg C, Rumsby G. Primary hyperoxaluria type 1: diagnostic relevance of mutations and polymorphisms in the alanine:glyoxylate aminotransferase gene (AGXT). J Inherit Metab Dis 1997; 20:689-96.

Tarr PE, Taffé P, Bleiber G et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk ofantiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191:1419-26.

Tarr PE, Telenti A. Toxicogenetics of antiretroviral therapy: genetic factors that contribute to metabolic complications. Antivir Ther 2007; 12:999-1013.

Taru H, Kirino Y, Suzuki T et al. Differential roles of JIP scaffold proteins in the modulation of amyloid precursor protein metabolism. J Biol Chem 2002; 277:27567-74.

Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y. Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 2000; 378:356-63.

Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol 2000; 49:139-44.

Tàssies D, Freire C, Pijoan J et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87:1185-91.

Tate SK, Depondt C, Sisodiya SM et al. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. Proc Nat Acad Sci USA 2005; 102:5507-12.

Tate SK, Singh R, Hung CC et al. A common polymorphism in the SCN1A gene associates with phenytoin serum levels at maintenance dose. Pharmacogenet Genomics 2006; 16:721-6.

Tate SK, Sisodiya SM. Multidrug resistance in epilepsy: a pharmacogenomic update. Expert Opin Pharmacother 2007; 8:1441-9.

Tatebayashi Y, Miyasaka T, Chui DH et al. Tau filament formation and associative memory déficit in aged mice expressing mutant (R406W) human tau. Proc Nat Acad Sci USA 2002; 99:13896-901.

Tateishi J, Brown P, Kitamoto T et al. First experimental transmission of fatal familial insomnia. Nature 1995; 376:434-5.

Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther 1999; 65:570-5.

Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesth Analg 1996; 82:167-72.

Tateishi T, Soucek P, Caraco Y, Guengerich FP, Wood AJ. Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochem Pharmacol 1997; 53:111-6.

Tateishi T, Watanabe M, Kumai T et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67:2913-20.

Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 1999; 57:935-9.

Tatematsu K, Koide A, Hirose M, Nishikawa A, Mori Y. Effect of cigarette smoke on mutagenic activation of environmental carcinogens by cytochrome P450 2A8 and inactivation by glucuronidation in hamster liver. Mutagenesis 2011; 26:323-30.

Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974; 43:339-57.

Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975; 24:44-53.

Tattersfield AE, Hall IP. Are beta2-adrenoceptor polymorphisms important in asthma-an unravelling story. Lancet 2004; 364:1464-6.

Tatuch Y, Christodoulou J, Feigenbaum A et al. Heteroplasmic mtDNA mutation (T-to-G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am J Hum Genet 1992; 50:852-8.

Tatum R, Zhang Y, Salleng K et al. Renal salt wasting and chronic dehydration in claudin-7-deficient mice. Am J Physiol Renal Physiol 2010; 298:24-34.

Taubert D, von Beckerath N, Grimberg G et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006; 80:486-501.

Taur JS, Desjardins CS, Schuck EL, Wong YN. Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells. Xenobiotica 2011; 41:320-6.

Tavridou A, Arvanitidis KI, Tiptiri-Kourpeti A et al. Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population. Diabetes Res Clin Pract 2009; 84:132-7.

Taxvig C, Elleby A, Sonne-Hansen K et al. Effects of nutrition relevant mixtures of phytoestrogens on steroidogenesis, aromatase, estrogen, and androgen activity. Nutr Cancer 2010; 62:122-31.

Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer 2003; 88:928-32.

Tayeb MT, Clark C, Sharp L et al. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 2002; 9:653-5.

Taylor AE, Guthrie PA, Smith GD et al. IQ, educational attainment, memory and plasma lipids: associations with Apolipoprotein E genotype in 5995 children. Biol Psychiatry 2011; 70:152-8.

Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171:109-12.

Taylor D, Bodani M, Hubbeling A, Murray R. The effect of nefazodone on clozapine plasma concentrations. Int Clin Psychopharmacol 1999; 14:185-7.

Taylor DP, Carter RB, Eison AS et al. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry 1995; 56 Suppl 6:3-11.

Taylor DR. Pharmacogenetics of beta2-agonist drugs in asthma. Clin Rev Allergy Immunol 2006; 31:247-58.

Taylor DR. beta-Adrenergic receptor polymorphisms: relationship to the beta-agonist controversy and clinical implications. Expert Opin Pharmacother 2007; 8:3195-203.

Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55:762-7.

Taylor DR, Epton MJ, Kennedy MA et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 2005; 172:700-3.

Taylor DR, Kennedy MA. Genetic variation of the beta(2)-adrenoceptor: its functional and clinical importance in bronchial asthma. Am J Pharmacogenomics 2001; 1:165-74.

Taylor GM, Dearden S, Ravetto P et al. Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201. Hum Mol Genet 2002; 11:1585-97.

Taylor GM, Hussain A, Lightfoot TJ, Birch JM, Eden TO, Greaves MF. HLA-associated susceptibility to childhood B-cell precursor ALL: definition and role of HLA-DPB1 supertypes. Br J Cancer 2008; 98:1125-31.

Taylor GM, Hussain A, Verhage V et al. Strong association of the HLA-DP6 supertype with childhood leukaemia is due to a single allele, DPB1*0601. Leukemia 2009; 23:863-9.

Taylor JG, Tang DC, Savage SA et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002; 100:4303-9.

Taylor JR, Brownlow N, Domin J, Dibb NJ. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 2006; 25:147-51.

Taylor KD, Scheuner MT, Yang H et al. Lipoprotein lipase locus and progression of atherosclerosis in coronary-artery bypass grafts. Genet Med 2004; 6:481-6.

Taylor M, Hussain A, Urayama K et al. The human major histocompatibility complex and childhood leukemia: an etiological hypothesis based on molecular mimicry. Blood Cells Mol Dis 2009; 42:129-35.

Taylor M, Lamb DC, Cannell R, Dawson M, Kelly SL. Cytochrome P450105D1 (CYP105D1) from Streptomyces griseus: heterologous expression, activity, and activation effects of multiple xenobiotics. Biochem Biophys Res Commun 1999; 263:838-42.

Taylor MR, Slavov D, Humphrey K et al. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics 2009; 19:35-43.

Taylor P, Li Y, Camp S et al. Structure and regulation of expression of the acetylcholinesterase gene. Chem Biol Interact 1993; 87:199-207.

Taylor RJ, Chan SL, Wood A et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009; 58:997-1006.

Taylor RW, Stewart MW, Avery PJ et al. Apolipoprotein E and familial non-insulin-dependent diabetes mellitus. Lancet 1994; 344:406.

Taylor TJ, Diringer K, Russell T et al. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. Clin Pharmacokinet 2006; 45:989-1001.

Tchernitchko D, Chiminqgi M, Galactéros F et al. Unexpected high frequency of P46L TNFRSF1A allele in sub-Saharan West African populations. Eur J Hum Genet 2005; 13:513-5.

Tchivileva IE, Lim PF, Smith SB et al. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics 2010; 20:239-48.

Tchoua U, Rosales C, Tang D et al. Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects. Lipids 2010; 45:1117-26.

Tchounwou PB, Yedjou CG, Foxx DN, Ishaque AB, Shen E. Lead-induced cytotoxicity and transcriptional activation of stress genes in human liver carcinoma (HepG2) cells. Mol Cell Biochem 2004; 255:161-70.

Teasdale GW, Nicoll JAR, Murray G, Fiddes M. Association of apolipoprotein E polymorphism with outcome after head injury. Lancet 1997; 350:1069-71.

Tefferi A. Modern diagnosis and treatment of primary eosinophilia. Acta Haematol 2005; 114:52-60.

Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 2011; 39:558-62.

Tegeder I, Adolph J, Schmidt H, Woolf CJ, Geisslinger G, Lötsch J. Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain 2008; 12:1069-77.

Tegeder I, Costigan M, Griffin RS et al. GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nat Med 2006; 12:1269-77.

Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, Burk O. Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine. Drug Metab Dispos 2007; 35:946-54.

Teh BT, Esapa CT, Houlston R et al. A family with isolated hyperparathyroidism segregating a missense MEN1 mutation and showing loss of the wild-type alleles in the parathyroid tumors. Am J Hum Genet 1998; 63:1544-9.

Teh LK, Ismail R, Yusoff R, Hussein A, Isa MN, Rahman AR. Heterogeneity of the CYP2D6 gene among Malays in Malaysia. J Clin Pharm Ther 2001; 26:205-11.

Teh LK, Langmia IM, Fazleen Haslinda MH et al. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. J Clin Pharm Ther 2011. doi:10. 1111/j. 1365-2710. 2011. 01262. x.

Teh LK, Zahri MK, Zakaria ZA, Ismail R, Salleh MZ. Mutational analysis of CYP2C8 in hypertensive patients using denaturing high performance liquid chromatography. J Clin Pharm Ther 2010; 35:723-8.

Teichert M, Eijgelsheim M, Rivadeneira F et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18:3758-68.

Teichert M, Eijgelsheim M, Uitterlinden AG et al. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. Pharmacogenet Genomics 2011; 21:26-34.

Teichert M, Visser LE, Uitterlinden AG et al. Selective serotonin reuptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol 2011; 72:798-805.

Teixeira RA, Odone-Filho V, de Camargo B et al. P-glycoprotein expression, tumor weight, age, and relapse in patients with stage I and II favorable-histology Wilms’ tumor. Pediatr Hematol Oncol 2011; 28:194-202.

Teksin ZS, Lee IJ, Nemieboka NN et al. Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen. Eur J Pharm Biopharm 2009; 72:471-7.

Telleria JJ, Blanco-Quirós A, Varillas D et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102:857-61.

Temelkova-Kurktschiev T, Hanefeld M, Chinetti G et al. Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis. J Clin Endocrinol Metab 2004; 89:4238-42.

Tempfer CB, Schneeberger C, Huber JC. Applications of polymorphisms and pharmacogenomics in obstetrics and gynecology. Pharmacogenomics 2004; 5:57-65.

Templeton IE, Thummel KE, Kharasch ED et al. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2008; 83:77-85.

Teng AC, Adamo K, Tesson F, Stewart AF. Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss. FASEB J 2009; 23:1705-9.

Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos 2003; 31:1296-9.

Tennezé L, Tarral E, Ducloux N, Funck-Brentano C. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 2002; 72:112-22.

Teo SK, Sabourin PJ, O’Brien K, Kook KA, Thomas SD. Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen’s disease patients. J Biochem Mol Toxicol 2000; 14:140-7.

Teodori E, Dei S, Martelli C, Scapecchi S, Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 2006; 7:893-909.

Teodori E, Dei S, Martelli C, Scapecchi S. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR). Curr Top Med Chem 2010; 10:1715-31.

Teoh CL, Griffin MD, Howlett GJ. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2011; 2:116-27.

Teoh H, Quan A, Bang KW et al. Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab 2008; 295:658-64.

Teoh H, Quan A, Lovren F et al. Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis 2008; 201:318-25.

Teotico DG, Bischof JJ, Peng L, Kliewer SA, Redinbo MR. Structural basis of human pregnane X receptor activation by the hops constituent colupulone. Mol Pharmacol 2008; 74:1512-20.

Tepper S, Allen C, Sanders D, Greene A, Boccuzzi S. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003; 43:44-8.

Tepper SJ. Safety and rational use of the triptans. Med Clin North Am 2001; 85:959-70.

Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003; 2:123-32.

Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002; 59:1084-8.

ter Heine R, Scherpbier HJ, Crommentuyn KM et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antivir Ther 2008; 13:779-87.

ter Laak MA, Temmink AH, Koeken A, van ‘t Veer NE, van Hattum PR, Cobbaert CM. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity. Pediatr Neurol 2010; 43:159-62.

Terada T, Irie M, Okuda M, Inui K. Genetic variant Arg57His in human H+/peptide cotransporter 2 causes a complete loss of transport function. Biochem Biophys Res Commun 2004; 316:416-20.

Terao T, Ohmori O, Shinkai T. A puzzling case of seizures and visual hallucinations during clomipramine treatment with a high dose but causing a low serum concentration. Acta Psychiatr Scand 1999; 99:388-90.

Terasaka N, Westerterp M, Koetsveld J et al. ATP-binding cassette transporter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010; 30:2219-25.

Terasaka N, Yu S, Yvan-Charvet L et al. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008; 118:3701-13.

Terashima M, Akita H, Kanazawa K et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99:2717-9.

Terheyden P, Houben R, Pajouh P, Thorns C, Zillikens D, Becker JC. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene. J Invest Dermatol 2010; 130:314-6.

Ternant D, Büchler M, Bénéton M et al. Interindividual variability in the concentration-effect relationship of antilymphocyte globulins – a possible influence of FcgammaRIIIa genetic polymorphism. Br J Clin Pharmacol 2008; 65:60-8.

Terpening C. Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol 2010; 4:117-28.

Terra SG, McGorray SP, Wu R et al. Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study. Int J Obes 2005; 29:746-54.

Terra SG, Pauly DF, Lee CR et al. Beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther 2005; 77:127-37.

Terret C, Zanetta S, Roché H et al. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG). Eur J Cancer 2003; 39:1097-104.

Terrier N, Benoit E, Senay C et al. Human and rat liver UDP-glucuronosyltransferases are targets of ketoprofen acylglucuronide. Mol Pharmacol 1999; 56:226-34.

Terry T, Chen Z, Dixon RA et al. CD34/M-cadherin bone marrow progenitor cells promote arteriogenesis in ischemic hindlimbs of ApoE mice. PLoS One 2011. doi:10. 1371/journal. pone. 0020673.

Terwel D, Steffensen KR, Verghese PB et al. Critical role of astroglial apolipoprotein E and liver X receptor-{alpha} expression for microglial A{beta} phagocytosis. J Neurosci 2011; 31:7049-59.

Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int 2010; 30:1270-9.

Teslovich TM, Musunuru K, Smith AV et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-13.

Tesson F, Donger C, Denjoy I et al. Exclusion of KCNE1 (IsK) as a candidate gene for Jervell and Lange-Nielsen syndrome. J Mol Cell Cardiol 1996; 28:2051-5.

Testa A, Mallamaci F, Benedetto FA et al. Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. J Bone Miner Res 2010; 25:313-9.

Testa A, Mallamaci F, Macrì R et al. Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. J Hypertens 2010; 28:1745-51.

Testa U, Stellacci E, Pelosi E et al. Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia 2004; 18:1864-71.

Tester R, Tan X, Luedtke GR et al. Amide-based inhibitors of p38alpha MAP kinase. Part 2: design, synthesis and SAR of potent N-pyrimidyl amides. Bioorg Med Chem Lett 2010; 20:2560-3.

Testino SA Jr, Patonay G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2003; 30:1459-67.

Tett SE, Saint-Marcoux F, Staatz CE et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev 2011; 25:47-57.

Teupser D, Mueller MA, Koglin J et al. CD36 mRNA expression is increased in CD14+ monocytes of patients with coronary heart disease. Clin Exp Pharmacol Physiol 2008; 35:552-6.

Teye K, Quaye IK, Koda Y et al. A-61C and C-101G Hp gene promoter polymorphisms are, respectively, associated with ahaptoglobinaemia and hypohaptoglobinaemia in Ghana. Clin Genet 2003; 64:439-43.

Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 2009; 69:443-8.

Thakker RV. Multiple endocrine neoplasia: syndromes of the twentieth century. J Clin Endocr Metab 1998; 83:2617-20.

Thakker-Varia S, Alder J. Neuropeptides in depression: role of VGF. Behav Brain Res 2009; 197:262-78.

Thakur GA, Grizenko N, Sengupta SM, Schmitz N, Joober R. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. BMC Psychiatry 2010; 10:50.

Tham LS, Holford NH, Hor SY et al. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin Cancer Res 2007; 13:7126-32.

Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther 2007; 82:555-65.

Thangaraju M, Ananth S, Martin PM et al. c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J Biol Chem 2006; 281:26769-73.

Thanopoulou K, Fragkouli A, Stylianopoulou F, Georgopoulos S. Scavenger receptor class B type I (SR-BI) regulates perivascular macrophages and modifies amyloid pathology in an Alzheimer mouse model. Proc Natl Acad Sci USA 2010; 107:20816-21.

Thanos PK, Rivera SN, Weaver K et al. Dopamine D2R DNA transfer in dopamine D2 receptor-deficient mice: effects on ethanol drinking. Life Sci 2005; 77:130-9.

Thapar MM, Ashton M, Lindegårdh N et al. Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur J Clin Pharmacol 2002; 58:19-27.

Tharoor H, Lobos EA, Todd RD, Reiersen AM. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008; 147:527-30.

Thasler WE, Dayoub R, Mühlbauer M et al. Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration. J Pharmacol Exp Ther 2006; 316:822-9.

Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol 2010; 80:903-12.

The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72:971-83.

Theile D, Grebhardt S, Haefeli WE, Weiss J. Involvement of drug transporters in the synergistic action of FOLFOX combination chemotherapy. Biochem Pharmacol 2009; 78:1366-73.

Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61:541-58.

Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM. In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions. Drug Metab Dispos 2009; 37:1286-94.

Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics 2008; 9:1285-306.

Theodoratos A, Whittle B, Enders A et al. Mouse strains with point mutations in TAP1 and TAP2. Immunol Cell Biol 2010; 88:72-8.

Theodoratou E, Campbell H, Tenesa A et al. Modification of the associations between lifestyle, dietary factors and colorectal cancer risk by APC variants. Carcinogenesis 2008; 29:1774-80.

Theodoropoulos C, Demers C, Delvin E, Ménard D, Gascon-Barré M. Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin Endocrinol 2003; 58:489-99.

Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005; 6:37-47.

Theuns J, Brouwers N, Engelborghs S et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. Am J Hum Genet 2006; 78:936-46.

Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45:649-63.

Thews O, Nowak M, Sauvant C, Gekle M. Hypoxia-induced extracellular acidosis increases p-Glycoprotein activity and chemoresistance in tumors in vivo via p38 signaling pathway. Adv Exp Med Biol 2011; 915:115-22.

Thi L, Shaw D, Bird J. Warfarin potentiation: a review of the “FAB-4” significant drug interactions. Consult Pharm 2009; 24:227-30.

Thiart R, Scholtz CL, Vergotine J et al. Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in Africans with familial hypercholesterolaemia. J Med Genet 2000; 37:514-9.

Thibaut R, Schnell S, Porte C. The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study. Environ Sci Technol 2006; 40:5154-60.

Thiel G, Lietz M, Cramer M. Biological activity and modulator structure of RE-1-silencing transcription factor (REST), a repressor of neuronal genes. J Biol Chem 1998; 273:26891-9.

Thieme D, Rolf B, Sachs H, Schmid D. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med 2008; 122:149-55.

Thier R, Brüning T, Roos PH et al. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes. Int J Hyg Environ Health 2003; 206:149-71.

Thigpen AE, Davis DL, Milatovich A et al. Molecular genetics of steroid 5 alpha-reductase 2 deficiency. J Clin Invest 1992; 90:799-809.

Thijssen HH, Drittij MJ, Vervoort LM, de Vries-Hanje JC. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70:292-8.

Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28:1284-90.

Thijssen HH, Ritzen B. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype. Clin Pharmacol Ther 2003; 74:61-8.

Thollet A, Vendrell JA, Payen L et al. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer 2010; 9:291.

Thomae BA, Rifki OF, Theobald MA, Eckloff BW, Wieben ED, Weinshilboum RM. Human catecholamine sulfotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. J Neurochem 2003; 87:809-19.

Thomas AR, Chan LN, Bauman JL, Olopade CO. Prolongation of the QT interval related to cisapride-diltiazem interaction. Pharmacotherapy 1998; 18:381-5.

Thomas DA. Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges. Hematology Am Soc Hematol Educ Program 2007:435-43.

Thomas G, Killeen MJ, Gurung IS et al. Mechanisms of ventricular arrhythmogenesis in mice following targeted disruption of KCNE1 modelling long QT syndrome 5. J Physiol 2007; 578:99-114.

Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenet Genomics 2007; 17:973-87.

Thomas IH, Saini NK, Adhikari A et al. Neonatal diabetes mellitus with pancreatic agenesis in an infant with homozygous IPF-1 Pro63fsX60 mutation. Pediatr Diabetes 2009; 10:492-6.

Thomas KL, Ellingrod VL. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions. Pharmacotherapy 2009; 29:822-31.

Thomas M, Halsall S, Peters TJ. Role of hepatic acetaldehyde dehydrogenase in alcoholism: demonstration of persistent reduction of cytosolic activity in abstaining patients. Lancet 1982; 2:1057-9.

Thomas NK, Brown TJ. ABC transporters do not contribute to extracellular translocation of hyaluronan in human breast cancer in vitro. Exp Cell Res 2010; 316:1241-53.

Thomas P, Rahman MS. Extensive reproductive disruption, ovarian masculinization and aromatase suppression in Atlantic croaker in the northern Gulf of Mexico hypoxic zone. Proc Biol Sci 2011. doi:10. 1098/rspb. 2011. 0529.

Thomas P, Srivastava V, Singh A et al. Correlates of response to olanzapine in a North Indian Schizophrenia sample. Psychiatry Res 2008; 161:275-83.

Thomas R, Apps R, Qi Y et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009; 41:1290-4.

Thomas RD, Green MR, Wilson C et al. Cytochrome P450 expression and metabolic activation of cooked food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in MCF10A breast epithelial cells. Chem Biol Interact 2006; 160:204-16.

Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J. Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 2006; 27:717.

Thome J, Retz W, Baader M et al. Association analysis of HTR6 and HTR2A polymorphisms in sporadic Alzheimer’s disease. J Neural Transm 2001; 108:1175-80.

Thompson AJ, Santoro R, Piazzolla V et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011; 53:389-95.

Thompson CM, Kawashima H, Strobel HW. Isolation of partially purified P450 2D18 and characterization of activity toward the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 1998; 359:115-21.

Thompson EE, Kuttab-Boulos H, Witonsky D, Yang L, Roe BA, Di Rienzo A. CYP3A variation and the evolution of salt-sensitivity variants. Am J Hum Genet 2004; 75:1059-69.

Thompson EE, Kuttab-Boulos H, Yang L, Roe BA, Di Rienzo A. Sequence diversity and haplotype structure at the human CYP3A cluster. Pharmacogenomics J 2006; 6:105-14.

Thompson JF, Man M, Johnson KJ et al. An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005; 5:352-8.

Thompson MD, Cole DE, Jose PA. Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. Methods Mol Biol 2008; 448:77-107.

Thompson MD, Percy ME, McIntyre Burnham W, Cole DE. G protein-coupled receptors disrupted in human genetic disease. Methods Mol Biol 2008; 448:109-37.

Thompson PD, Jurutka PW, Whitfield GK et al. Liganded VDR induces CYP3A4 in small intestinal and colon cancer cells via DR3 and ER6 vitamin D responsive elements. Biochem Biophys Res Commun 2002; 299:730-8.

Thompson PD, Tsongalis GJ, Seip RL et al. Apolipoprotein E genotype and changes in serum lipids and maximal oxygen uptake with exercise training. Metabolism 2004; 53:193-202.

Thorgeirsson TE, Gudbjartsson DF, Surakka et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat Genet 2010; 42:448-53.

Thorleifsson G, Magnusson KP, Sulem P et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007; 317:1397-400.

Thorn CF, Klein TE, Altman RB. Codeine and morphine pathway. Pharmacogenet Genomics 2009; 19:556-8.

Thorn CF, Lamba JK, Lamba V, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenet Genomics 2010; 20:520-3.

Thorn CF, Whitehead AS. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. J Immunol 2002; 169:399-406.

Thörn HA, Lundahl A, Schrickx JA, Dickinson PA, Lennernäs H. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. Eur J Pharm Sci 2011; 43:89-98.

Thörn M, Finnström N, Lundgren S, Rane A, Lööf L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005; 60:54-60.

Thörn M, Finnström N, Lundgren S, Rane A, Lööf L. Expression of cytochrome P450 and MDR1 in patients with proctitis. Ups J Med Sci 2007; 112:303-12.

Thörn M, Lundgren S, Herlenius G, Ericzon BG, Lööf L, Rane A. Gene expression of cytochromes P450 in liver transplants over time. Eur J Clin Pharmacol 2004; 60:413-20.

Thornton-Manning JR, Ruangyuttikarn W, Gonzalez FJ, Yost GS. Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s. Biochem Biophys Res Commun 1991; 181:100-7.

Thresher R, Gurney R, Canning M. Effects of lifetime chemical inhibition of aromatase on the sexual differentiation, sperm characteristics and fertility of medaka (Oryzias latipes) and zebrafish (Danio rerio). Aquat Toxicol 2011; 105:355-60.

Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. Environ Health Perspect 2006; 114:1655-61.

Thummel KE. Gut instincts: CYP3A4 and intestinal drug metabolism. J Clin Invest 2007; 117:3173-6.

Thummel KE, Brimer C, Yasuda K et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol 2001; 60:1399-406.

Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol 1993; 45:1563-9.

Thummel KE, Shen DD, Podoll TD et al. Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994; 271:557-66.

Thursz M, Yallop R, Goldin R, Trepo C, Thomas HC. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet 1999; 354:2119-24.

Thye T, Browne EN, Chinbuah MA et al. IL10 haplotype associated with tuberculin skin test response but not with pulmonary TB. PLoS One 2009. doi:10. 1371/journal. pone. 0005420.

Tian H, Ru S, Wang W, Bing X. Effects of monocrotophos on the reproductive axis in the female goldfish (Carassius auratus). Comp Biochem Physiol C Toxicol Pharmacol 2010; 152:107-13.

Tian X, Swift B, Zamek-Gliszczynski MJ, Belinsky MG, Kruh GD, Brouwer KL. Impact of basolateral multidrug resistance-associated protein (Mrp) 3 and Mrp4 on the hepatobiliary disposition of fexofenadine in perfused mouse livers. Drug Metab Dispos 2008; 36:911-5.

Tian XL, Pinto YM, Costerousse O et al. Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats. Hum Mol Genet 2004; 13:1441-50.

Tianpanich K, Prachya S, Wiyakrutta S, Mahidol C, Ruchirawat S, Kittakoop P. Radical scavenging and antioxidant activities of isocoumarins and a phthalide from the endophytic fungus Colletotrichum sp. J Nat Prod 2011; 74:79-81.

Tidcombe H, Jackson-Fisher A, Mathers K, Stern DF, Gassmann M, Golding JP. Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality. Proc Natl Acad Sci USA 2003; 100:8281-6.

Tikka-Kleemola P, Kaunisto MA, Hämäläinen E et al. Genetic association study of endothelin-1 and its receptors EDNRA and EDNRB in migraine with aura. Cephalalgia 2009; 29:1224-31.

Tikkanen R, Sjöberg RL, Ducci F et al. Effects of MAOA-genotype, alcohol consumption, and aging on violent behavior. Alcohol Clin Exp Res 2009; 33:428-34.

Timm R, Kaiser R, Lötsch J et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J 2005; 5:365-73.

Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38:461-74.

Timofeeva MN, Kropp S, Sauter W et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis 2009; 30:1161-9.

Tin MK, Hakki T, Bernhardt R. Fission yeast Schizosaccharomyces pombe as a new system for the investigation of corticosterone methyloxidase deficiency-causing mutations. J Steroid Biochem Mol Biol 2011; 124:31-7.

Tinel N, Diochot S, Borsotto M, Lazdunski M, Barhanin J. KCNE2 confers background current characteristics to the cardiac KCNQ1 potassium channel. EMBO J 2000; 19:6326-30.

Ting LS, Benoit-Biancamano MO, Bernard O, Riggs KW, Guillemette C, Ensom MH. Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. Pharmacotherapy 2010; 30:1097-108.

Ting TC, Miyazaki-Anzai S, Masuda M et al. Increased lipogenesis and stearate accelerate vascular calcification in calcifying vascular cells. J Biol Chem 2011; 286:23938-49.

Tiong K, Falhammar H. Carbamazepine and falsely positive screening tests for Cushing’s syndrome. N Z Med J 2009; 122:100-2.

Tiong KH, Yiap BC, Tan EL, Ismail R, Ong CE. Functional characterization of cytochrome P450 2A6 allelic variants CYP2A6*15, CYP2A6*16, CYP2A6*21, and CYP2A6*22. Drug Metab Dispos 2010; 38:745-51.

Tiong KH, Yiap BC, Tan EL, Ismail R, Ong CE. In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity. Xenobiotica 2010; 40:458-66.

Tiranti V, Carrara F, Confalonieri P et al. A novel mutation (8342G→A) in the mitochondrial tRNA(Lys) gene associated with progressive external ophthalmoplegia and myoclonus. Neuromuscul Disord 1999; 9:66-71.

Tirelli V, Catone T, Turco L, Di Consiglio E, Testai E, de Angelis I. Effects of the pesticide clorpyrifos on an in vitro model of intestinal barrier. Toxicol In Vitro 2007; 21:308-13.

Tiribelli M, Geromin A, Michelutti A et al. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer 2011; 117:2156-62.

Tirkkonen T, Heikkilä P, Huupponen R, Laine K. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J Intern Med 2010; 268:359-66.

Tirkkonen T, Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther 2004; 76:639-47.

Tirkkonen T, Ryynänen A, Vahlberg T et al. Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study. Drug Saf 2008; 31:231-40.

Tiroch KA, Sibbing D, Koch W et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 2010; 160:506-12.

Tirona RG, Lee W, Leake BF et al. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003; 9:220-4.

Tiwari AK, Deshpande SN, Rao AR et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 2005; 75:21-6.

Tiwari AK, Souza RP, Müller DJ. Pharmacogenetics of anxiolytic drugs. J Neural Transm 2009; 116:667-77.

Tiwari AK, Zai CC, Likhodi O et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010; 35:1315-24.

Tiwari AK, Zai CC, Likhodi O et al. Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J 2011. doi:10. 1038/tpj. 2010. 93.

Tiwari MN, Singh AK, Ahmad I et al. Effects of cypermethrin on monoamine transporters, xenobiotic metabolizing enzymes and lipid peroxidation in the rat nigrostriatal system. Free Radic Res 2010; 44:1416-24.

Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996; 276:912-7.

Tlaskalová-Hogenová H, Stěpánková R, Kozáková H et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 2011; 8:110-20.

To AW, Ribe EM, Chuang TT, Schroeder JE, Lovestone S. The ε3 and ε4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One 2011. doi:10. 1371/journal. pone. 0016991.

To KK, Robey R, Zhan Z, Bangiolo L, Bates SE. Upregulation of ABCG2 by romidepsin via the aryl hydrocarbon receptor pathway. Mol Cancer Res 2011; 9:516-27.

To MD, Wong CE, Karnezis AN, del Rosario R, di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 2008; 40:1240-4.

Tobin JE, Latourelle JC, Lew MF et al. Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology 2008; 71:28-34.

Tobin MD, Timpson NJ, Wain LV et al. Common variation in the WNK1 gene and blood pressure in childhood: the Avon longitudinal study of parents and children. Hypertension 2008; 52:974-9.

Toda T, Ohi K, Kudo T et al. Antibiotics suppress Cyp3a in the mouse liver by reducing lithocholic acid-producing intestinal flora. Yakugaku Zasshi 2009; 129:601-8.

Todorova B, Kubaszek A, Pihlajamäki J et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 2004; 89:2019-23.

Todt U, Freudenberg J, Goebel I et al. MTHFR C677T polymorphism and migraine with aura. Ann Neurol 2006; 60:621-2.

Toffoli B, Bernardi S, Candido R, Zacchigna S, Fabris B, Secchiero P. TRAIL shows potential cardioprotective activity. Invest New Drugs 2011. doi:10. 1007/s10637-010-9627-8.

Toffoli B, Pickering RJ, Tsorotes D et al. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. Atherosclerosis 2011; 218:61-8.

Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents 2003; 3:225-37.

Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010; 56:696-708.

Toguchida J, Yamaguchi T, Ritchie B et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 1992; 52:6194-9.

Toh S, Wada M, Uchiumi T et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64:739-46.

Tojcic J, Benoit-Biancamano MO, Court MH, Straka RJ, Caron P, Guillemette C. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 2009; 37:2236-43.

Tokairin T, Fukasawa T, Yasui-Furukori N et al. Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol 2005; 60:172-5.

Tokar EJ, Diwan BA, Waalkes MP. Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect 2010; 118:108-15.

Tokar EJ, Qu W, Liu J et al. Arsenic-specific stem cell selection during malignant transformation. J Natl Cancer Inst 2010; 102:638-49.

Tokita K, Schmid K. Variants of Alpha-1-acid glycoprotein. Nature 1963; 200:266.

Tokiwa T, Yamazaki T, Ono M, Enosawa S, Tsukiyama T. Cloning and characterization of liver progenitor cells from the scattered cell clusters in primary culture of porcine livers. Cell Transplant 2008; 17:179-86.

Tokiwa T, Yamazaki T, Xin W et al. Differentiation potential of an immortalized non-tumorigenic human liver epithelial cell line as liver progenitor cells. Cell Biol Int 2006; 30:992-8.

Tokura T, Itano S, Kobayashi S et al. A novel mutation ApoE2 Kurashiki (R158P) in a patient with lipoprotein glomerulopathy. J Atheroscler Thromb 2011; 18:536-41.

Tolonen A, Petsalo A, Turpeinen M, Uusitalo J, Pelkonen O. In vitro interaction cocktail assay for nine major cytochrome P450 enzymes with 13 probe reactions and a single LC/MSMS run: analytical validation and testing with monoclonal anti-CYP antibodies. J Mass Spectrom 2007; 42:960-6.

Tolonen S, Mikkilä V, Laaksonen M et al. Association of apolipoprotein E promoter polymorphisms with bone structural traits is modified by dietary saturated fat intake – the Cardiovascular Risk in Young Finns Study. Bone 2011; 48:1058-65.

Tolson AH, Li H, Eddington ND, Wang H. Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos 2009; 37:1887-94.

Tolstrup JS, Grønbaek M, Nordestgaard BG. Alcohol intake, myocardial infarction, biochemical risk factors, and alcohol dehydrogenase genotypes. Circ Cardiovasc Genet 2009; 2:507-14.

Tolstrup JS, Nordestgaard BG, Rasmussen S, Tybjaerg-Hansen A, Grønbaek M. Alcoholism and alcohol drinking habits predicted from alcohol dehydrogenase genes. Pharmacogenomics J 2008; 8:220-7.

Tollefsen S, Arentz-Hansen H, Fleckenstein B et al. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J Clin Invest 2006; 116:2226-36.

Tomalik-Scharte D, Fuhr U, Hellmich M et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug Metab Dispos 2011; 39:927-32.

Tomalik-Scharte D, Jetter A, Kinzig-Schippers M et al. Effect of propiverine on cytochrome P450 enzymes: a cocktail interaction study in healthy volunteers. Drug Metab Dispos 2005; 33:1859-66.

Tomalik-Scharte D, Maiter D, Kirchheiner J, Ivison HE, Fuhr U, Arlt W. Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency. Eur J Endocrinol 2010; 163:919-24.

Tomboc M, Witchel SF. Frequencies of the D85 and Y85 variants of UGT2B15 in children and adolescent girls with hyperandrogenism. J Pediatr Endocrinol Metab 2003; 16:719-26.

Tomei L, Eap CB, Baumann P, Dente L. Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. Hum Genet 1989; 84:89-91.

Tomic Z, Milijasevic B, Sabo A et al. Diclofenac and ketoprofen liver toxicity in rat. Eur J Drug Metab Pharmacokinet 2008; 33:253-60.

Tomicic C, Berode M, Oppliger A et al. Sex differences in urinary levels of several biological indicators of exposure: a human volunteer study. Toxicol Lett 2011; 202:218-25.

Tomimoto H, Akiguchi I, Suenaga T et al. Immunohistochemical study of apolipoprotein E in human cerebrovascular white matter lesions. Acta Neopath 1995; 90:608-14.

Tomino Y, Makita Y, Shike T et al. Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 1999; 82:139-44.

Tomita M, Doi N, Hayashi M. Effects of acylcarnitines on efflux transporting system in Caco-2 cell monolayers. Eur J Drug Metab Pharmacokinet 2010; 35:1-7.

Tomita M, Kanbayashi A, Murata H et al. Effect of lipopolysaccharide on P-glycoprotein-mediated intestinal and biliary excretion of rhodamine123 in rats. Int J Pharm 2010; 392:35-41.

Tomita M, Kishimoto H, Takizawa Y, Hayashi M. Effects of intestinal ischemia/reperfusion on P-glycoprotein mediated biliary and renal excretion of rhodamine123 in rat. Drug Metab Pharmacokinet 2009; 24:428-37.

Tomita M, Watanabe A, Fujinaga I, Yamakawa T, Hayashi M. Nonlinear absorption of methylprednisolone by absorptive and secretory transporters. Int J Pharm 2010; 387:1-6.

Tomitaka M, Tomitaka S, Otuka Y et al. Association between novelty seeking and dopamine receptor D4 (DRD4) exon III polymorphism in Japanese subjects. Am J Med Genet 1999; 88:469-71.

Tomiyasu H, Goto-Koshino Y, Takahashi M, Fujino Y, Ohno K, Tsujimoto H. Quantitative analysis of mRNA for 10 different drug resistance factors in dogs with lymphoma. J Vet Med Sci 2010; 72:1165-72.

Tomlinson B, Hu M, Lee VW et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther 2010; 87:558-62.

Tomlinson ES, Lewis DF, Maggs JL, Kroemer HK, Park BK, Back DJ. In vitro metabolism of dexamethasone (DEX) in human liver and kidney: the involvement of CYP3A4 and CYP17 (17,20 LYASE) and molecular modelling studies. Biochem Pharmacol 1997; 54:605-11.

Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism in vitro: species differences. J Steroid Biochem Mol Biol 1997; 62:345-52.

Tommasi AM, Fabris P, Carderi I et al. Lack of higher frequency of the chemokine receptor 5-delta32/delta32 genotype in hepatitis C. J Clin Gastroenterol 2006; 40:440-3.

Tompkins JB, Stitt LE, Morrissette AM, Ardelli BF. The role of Brugia malayi ATP-binding cassette (ABC) transporters in potentiating drug sensitivity. Parasitol Res 2011; 109:1311-22.

Tompkins LM, Sit TL, Wallace AD. Unique transcription start sites and distinct promoter regions differentiate the pregnane X receptor (PXR) isoforms PXR 1 and PXR 2. Drug Metab Dispos 2008; 36:923-9.

Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem Mol Toxicol 2007; 21:176-81.

Tonack S, Patel S, Jalali M et al. Tetracycline-inducible protein expression in pancreatic cancer cells: effects of CapG overexpression. World J Gastroenterol 2011; 17:1947-60.

Tong MH, Jiang H, Liu P, Lawson JA, Brass LF, Song WC. Spontaneous fetal loss caused by placental thrombosis in estrogen sulfotransferase-deficient mice. Nat Med 2005; 11:153-9.

Tong W, Chowdhury SK, Su AD, Feng W, Ghosal A, Alton KB. Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration. J Mass Spectrom 2006; 41:1430-41.

Tonge RP, Kelly EJ, Bruschi SA et al. Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigations using Cyp1a2 null mice. Toxicol Appl Pharmacol 1998; 153:102-8.

Tonini M, de Ponti F, Di Nucci A, Crema F. Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 1999; 13:1585-91.

Toogood PL, Harvey PJ, Repine JT et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 2005; 48:2388-406.

Toon S, Heimark LD, Trager WF, O’Reilly RA. Metabolic fate of phenprocoumon in humans. J Pharm Sci 1985; 74:1037-40.

Topic Popovic N, Babish JG, Bowser PR. Observational study of hepatic cytochrome P-450 protein expression and activity in summer flounder (Paralichtys dentatus) after combination ormetoprim-sulfadimethoxine treatment. Chemotherapy 2007; 53:313-5.

Topic Popovic N, Howell T, Babish JG, Bowser PR. Cross-sectional study of hepatic CYP1A and CYP3A enzymes in hybrid striped bass, channel catfish and Nile tilapia following oxytetracycline treatment. Res Vet Sci 2011. doi:10. 1016/j. rvsc. 2011. 03. 003.

Torielli L, Tivodar S, Montella RC et al. Alpha-adducin mutations increase Na/K pump activity in renal cells by affecting constitutive endocytosis: implications for tubular Na reabsorption. Am J Physiol Renal Physiol 2008; 295:478-87.

Torimoto N, Ishii I, Hata M et al. Direct interaction between substrates and endogenous steroids in the active site may change the activity of cytochrome P450 3A4. Biochemistry 2003; 42:15068-77.

Torimoto N, Ishii I, Hata M et al. Theoretical calculation of triazolam hydroxylation and endogenous steroid inhibition in the active site of CYP3A4. Biochim Biophys Acta 2007; 1774:223-32.

Torimoto N, Ishii I, Toyama K et al. Helices F-G are important for the substrate specificities of CYP3A7. Drug Metab Dispos 2007; 35:484-92.

Toriyabe T, Nagata K, Takada T et al. Unveiling a new essential cis element for the transactivation of the CYP3A4 gene by xenobiotics. Mol Pharmacol 2009; 75:677-84.

Torley KJ, da Silveira JC, Smith P et al. Expression of miRNAs in ovine fetal gonads: potential role in gonadal differentiation. Reprod Biol Endocrinol 2011; 9:2.

Torlontano M, Durante C, Torrente I et al. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008; 93:910-3.

Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 2006; 62:645-51.

Tornio A, Niemi M, Neuvonen PJ, Backman JT. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008; 36:73-80.

Torres-Galván SM, Cumplido JA, Buset N et al. 5-Lipoxygenase pathway gene polymorphisms: lack of association with asthma in a Spanish population. J Investig Allergol Clin Immunol 2009; 19:453-8.

Torres-Romero D, Muñoz-Martínez F, Jiménez IA, Castanys S, Gamarro F, Bazzocchi IL. Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance. Org Biomol Chem 2009; 7:5166-72.

Torroni A, Petrozzi M, D’Urbano L et al. Haplotype and phylogenetic analyses suggest that one European-specific mtDNA background plays a role in the expression of Leber hereditary optic neuropathy by increasing the penetrance of the primary mutations 11778 and 14484. Am J Hum Genet 1997; 60:1107-21.

Tosca L, Chabrolle C, Uzbekova S, Dupont J. Effects of metformin on bovine granulosa cells steroidogenesis: possible involvement of adenosine 5’ monophosphate-activated protein kinase (AMPK). Biol Reprod 2007; 76:368-78.

Tosca L, Solnais P, Ferré P, Foufelle F, Dupont J. Metformin-induced stimulation of adenosine 5’ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod 2006; 75:342-51.

Toscano C, Klein K, Blievernicht J et al. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 2006; 16:755-66.

Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, Zanger UM. A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenet Genomics 2006; 16:767-70.

Toselli F, Matthias A, Bone KM, Gillam EM, Lehmann RP. Metabolism of the major Echinacea alkylamide N-isobutyldodeca-2E,4E,8Z,10Z-tetraenamide by human recombinant cytochrome P450 enzymes and human liver microsomes. Phytother Res 2010; 24:1195-201.

Totah RA, Allen KE, Sheffels P, Whittington D, Kharasch ED. Enantiomeric metabolic interactions and stereoselective human methadone metabolism. J Pharmacol Exp Ther 2007; 321:389-99.

Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108:363-74.

Tóth M, Bajnógel J, Egyed A, Drabant S, Tömlo J, Klebovich I. Effect of tofisopam on CYP3A4 enzyme activity on human recombinant 3A4 supersome. Acta Pharm Hung 2005; 75:195-8.

Tóth M, Drabant S, Varga B et al. Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam. Eur J Clin Pharmacol 2008; 64:93-4.

Totlandsdal AI, Cassee FR, Schwarze P, Refsnes M, Låg M. Diesel exhaust particles induce CYP1A1 and pro-inflammatory responses via differential pathways in human bronchial epithelial cells. Part Fibre Toxicol 2010; 7:41.

Touma Z, Farra C, Hamdan A et al. TNF polymorphisms in patients with Behçet disease: a meta-analysis. Arch Med Res 2010; 41:142-6.

Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X. Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol 2010; 13:905-15.

Tournier N, Valette H, Peyronneau MA et al. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med 2011; 52:415-23.

Touvier M, Chan DS, Lau RN et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2011; 20:1003-16.

Town T, Laouar Y, Pittenger C et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008; 6:681-7.

Townsend KP, Praticò D. Novel therapeutic opportunities for Alzheimer’s disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J 2005; 19:1592-601.

Toy EP, Chambers JT, Kacinski BM, Flick MB, Chambers SK. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 80:194-200.

Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol 2009; 39:651-6.

Toyoda Y, Hagiya Y, Adachi T, Hoshijima K, Kuo MT, Ishikawa T. MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica 2008; 38:833-62.

Toyofyuku M, Imazu M, Sumii K et al. Influence of angiotensinogen M253T gene polymorphism and an angiotensin converting enzyme inhibitor on restenosis after percutaneous coronary intervention. Atherosclerosis 2002; 160:339-44.

Toyota T, Hattori E, Meerabux J et al. Molecular analysis, mutation screening, and association study of adenylate cyclase type 9 gene (ADCY9) in mood disorders. Am J Med Genet 2002; 114:84-92.

Tozzi V. Pharmacogenetics of antiretrovirals. Antiviral Res 2010; 85:190-200.

Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30:385-90.

Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 1997; 52:293-8.

Tracy TS, Venkataramanan R, Glover DD, Caritis SN; National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Units. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005; 192:633-9.

Trachet B, Renard M, de Santis G et al. An integrated framework to quantitatively link mouse-specific hemodynamics to aneurysm formation in angiotensin II-infused ApoE -/- mice. Ann Biomed Eng 2011; 39:2430-44.

Trafalis DT, Panteli ES, Grivas A, Tsigris C, Karamanakos PN. CYP2E1 and risk of chemically mediated cancers. Expert Opin Drug Metab Toxicol 2010; 6:307-19.

Tran A, Jullien V, Alexandre J et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther 2006; 79:570-80.

Tran A, Rey E, Pons G et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther 1997; 62:490-504.

Tran A, Tréluyer JM, Rey E et al. Protective effect of stiripentol on acetaminophen-induced hepatotoxicity in rat. Toxicol Appl Pharmacol 2001; 170:145-52.

Tran CD, Timmins P, Conway BR, Irwin WJ. Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells. J Pharm Sci 2002; 91:117-28.

Tran JQ, Di Cicco RA, Sheth SB et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999; 39:513-9.

Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2001; 40:207-26.

Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 1999; 39:487-94.

Tran PV, Georgieff MK, Engeland WC. Sodium depletion increases sympathetic neurite outgrowth and expression of a novel TMEM35 gene-derived protein (TUF1) in the rat adrenal zona glomerulosa. Endocrinology 2010; 151:4852-60.

Tran QT, Xu L, Phan V et al. Chemical genomics of cancer chemopreventive dithiolethiones. Carcinogenesis 2009; 30:480-6.

Tran VH, Marks D, Duke RK, Bebawy M, Duke CC, Roufogalis BD. Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions. Nutr Cancer 2011; 63:435-43.

Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur J Clin Pharmacol 1996; 51:79-85.

Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50:209-15.

Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58:412-7.

Trapnell CB, Connolly M, Pentikis H, Forbes WP, Bettenhausen DK. Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females. Ann Pharmacother 2007; 41:222-8.

Traver RD, Horikoshi T, Danenberg KD et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992; 52:797-802.

Traver RD, Siegel D, Beall HD et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997; 75:69-75.

Travers MT, Cambot M, Kennedy HT et al. Asymmetric expression of transcripts derived from the shared promoter between the divergently oriented ACACA and TADA2L genes. Genomics 2005; 85:71-84.

Trdan Lusin T, Trontelj J, Mrhar A. Raloxifene glucuronidation in human intestine, kidney and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 2011. doi:10. 1124/dmd. 111. 041897.

Treacy EP, Akerman BR, Chow LM et al. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 1998; 7:839-45.

Trebino CE, Stock JL, Gibbons CP et al. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Nat Acad Sci USA 2003; 100:9044-9.

Treeck O, Elemenler E, Kriener C et al. Polymorphisms in the promoter region of ESR2 gene and breast cancer susceptibility. J Steroid Biochem Mol Biol 2009; 114:207-11.

Treiber A, Schneiter R, Delahaye S, Clozel M. Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat. J Pharmacol Exp Ther 2004; 308:1121-9.

Treiber A, Schneiter R, Häusler S, Stieger B. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007; 35:1400-7.

Treloar A, Assin M, MacDonald A et al. Pupillary response to topical tropicamide as a marker of Alzheimer’s disease. Br J Clin Pharmacol 1996; 41:256-7.

Tréluyer JM, Bowers G, Cazali N et al. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos 2003; 31:275-81.

Tréluyer JM, Rey E, Sonnier M, Pons G, Cresteil T. Evidence of impaired cisapride metabolism in neonates. Br J Clin Pharmacol 2001; 52:419-25.

Trenk D, Hochholzer W, Fromm MF et al. Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement. Circ Cardiovasc Genet 2011; 4:429-36.

Trenk D, Hochholzer W, Frundi D et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008; 99:174-81.

Trenton A, Currier G, Zwemer F. Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 2003; 17:307-24.

Trettel F, Rigamonti D, Hilditch-Maguire P et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Molec Genet 2000; 9:2799-809.

Treutlein J, Cichon S, Ridinger M et al. Genome-wide association study of alcohol dependence. Arch Gen Psychiatry 2009; 66:773-84.

Triantis V, Saeland E, Bijl N, Oude-Elferink RP, Jansen PL. Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1. Hepatology 2010; 52:656-66.

Trifunovic A, Wredenberg A, Falkenberg M et al. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 2004; 429:417-23.

Trilecová L, Krcková S, Marvanová S et al. Toxic effects of methylated benzo[a]pyrenes in rat liver stem-like cells. Chem Res Toxicol 2011; 24:866-876.

Trimbath JD, Petersen GM, Erdman SH, Ferre M, Luce MC, Giardiello FM. Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer 2001; 1:101-5.

Tringali C, Lupo B, Anastasia L et al. Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling. J Biol Chem 2007; 282:14364-72.

Tripodi G, Modica R, Stella A, Bigatti G, Bianchi G, Stella P. Haplotype analysis of carnitine transporters and left ventricular mass in human essential hypertension. J Ren Nutr 2005; 15:2-7.

Trobridge P, Knoblaugh S, Washington MK et al. TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 2009; 136:1680-8.

Tröbs L, Henkelmann B, Lenoir D, Reischl A, Schramm KW. Degradative fate of 3-chlorocarbazole and 3,6-dichlorocarbazole in soil. Environ Sci Pollut Res Int 2011; 18:547-55.

Troncoso R, Moraga F, Chiong M et al. Gln(27)→Glubeta(2)-adrenergic receptor polymorphism in heart failure patients: differential clinical and oxidative response to carvedilol. Basic Clin Pharmacol Toxicol 2009; 104:374-8.

Tronche F, Opherk C, Moriggl R et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev 2004; 18:492-7.

Troost J, Tatami S, Tsuda Y et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol 2011; 72:247-56.

Troost PW, Lahuis BE, Hermans MH et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27:52-7.

Trottier J, El Husseini D, Perreault M et al. The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver. J Biol Chem 2010; 285:1113-21.

Trottier Y, Biancalana V, Mandel J. Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. J Med Genet 1994; 31:377-82.

Trottier Y, Devys D, Imbert G et al. Cellular localization of the Huntington’s disease protein and discrimination of the normal and mutated form. Nat Genet 1995; 10:104-10.

Troy CM, Rabacchi SA, Xu Z et al. Beta-amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001; 77:157-64.

Trubetskoy O, Marks B, Zielinski T, Yueh MF, Raucy J. A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. AAPS J 2005; 7:6-13.

Trubetskoy OV, Gibson JR, Marks BD. Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen 2005; 10:56-66.

Trubicka J, Grabowska-Kłujszo E, Suchy J et al. Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer 2010; 10:420.

True HL, Lindquist SL. An yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 2000; 407:477-83.

Trüeb RM. Hormones and hair growth. Hautarzt 2010; 61:487-95.

Trusca VG, Fuior EV, Florea IC, Kardassis D, Simionescu M, Gafencu AV. Macrophage-specific Up-regulation of Apolipoprotein E gene expression by STAT1 is achieved via long range genomic interactions. J Biol Chem 2011; 286:13891-904.

Trusov NV, Guseva GV, Aksenov IV, Avren’eva LI, Kravchenko LV, Tutelyan VA. Effects of combined treatment with resveratrol and indole-3-carbinol. Bull Exp Biol Med 2010; 149:213-8.

Tryggvason G, Hilmarsdottir B, Gunnarsson GH, Jónsson JJ, Jónasson JG, Magnússon MK. Tyrosine kinase mutations in gastrointestinal stromal tumors in a nation-wide study in Iceland. APMIS 2010; 118:648-56.

Tsai CT, Hwang JJ, Chiang FT et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation: a regression approach for the detection of gene-gene interactions in a large hospitalized population. Cardiology 2008; 111:1-7.

Tsai CT, Hwang JJ, Ritchie MD et al. Renin-angiotensin system gene polymorphisms and coronary artery disease in a large angiographic cohort: detection of high order gene-gene interaction. Atherosclerosis 2007; 195:172-80.

Tsai CH, Tung KY, Chen CH, Lee YL. Tumour necrosis factor G-308A polymorphism modifies the effect of home dampness on childhood asthma. Occup Environ Med 2011; 68:771-6.

Tsai G, Crisostomo G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995; 7:91-5.

Tsai HJ, Shaikh N, Kho JY et al. Study of African Americans, asthma, genes environments (SAGE): Beta-2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet 2006; 119:547-57.

Tsai JY, Su KH, Shyue SK et al. EGb761 ameliorates the formation of foam cells by regulating the expression of SR-A and ABCA1: role of haem oxygenase-1. Cardiovasc Res 2010; 88:415-23.

Tsai LL, Yu CC, Chang YC, Yu CH, Chou MY. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. J Oral Pathol Med 2011; 40:621-8.

Tsai MH, Lin KM, Hsiao MC et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11:537-46.

Tsai MS, Chiu YT, Wang SH, Hsieh-Li HM, Li H. Abolishing Trp53-dependent apoptosis does not benefit spinal muscular atrophy model mice. Eur J Hum Genet 2006; 14:372-5.

Tsai MY, Bignell M, Yang F, Welge BG, Graham KJ, Hanson NQ. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine beta-synthase and A(2756)G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 2000; 149:131-7.

Tsai MY, Ordovas JM, Li N et al. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab 2010; 100:118-22.

Tsai SJ, Hong CJ, Chen TJ, Yu YW. Lack of supporting evidence for a genetic association of the FKBP5 polymorphism and response to antidepressant treatment. Am J Med Genet B Neuropsychiatr Genet 2007; 144:1097-8.

Tsai SJ, Hong CJ, Liou YJ. Brain-derived neurotrophic factor and antidepressant action: another piece of evidence from pharmacogenetics. Pharmacogenomics 2008; 9:1353-8.

Tsai SJ, Hong CJ, Liou YJ et al. Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:637-41.

Tsai SJ, Liou YJ, Hong CJ, Yu YW, Chen TJ. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 2008; 8:384-90.

Tsai SJ, Liu HC, Liu TY, Wang YC, Hong CJ. Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer’s disease. Neurosci Lett 1999; 276:138-9.

Tsai SJ, Wang YC, Yu Younger WY, Lin CH, Yang KH, Hong CJ. Association analysis of polymorphism in the promoter region of the alpha2a-adrenoceptor gene with schizophrenia and clozapine response. Schizophr Res 2001; 49:53-8.

Tsai SJ, Yu YW, Lin CH, Wang YC, Chen JY, Hong CJ. Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment. Neuropsychobiology 2004; 50:37-40.

Tsai SM, Lin CY, Wu SH et al. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 2009; 404:160-5.

Tsalkova TN, Davydova NY, Halpert JR, Davydov DR. Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe. Biochemistry 2007; 46:106-19.

Tsang TY, Tang WY, Chan JY et al. P-glycoprotein enhances radiation-induced apoptotic cell death through the regulation of miR-16 and Bcl-2 expressions in hepatocellular carcinoma cells. Apoptosis 2011; 16:524-35.

Tsao YY, Gugger JJ. Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Ann Pharmacother 2009; 43:1366-9.

Tsatsakis AM, Androutsopoulos VP, Zafiropoulos A et al. Associations of xenobiotic-metabolizing enzyme genotypes PON1Q192R, PON1L55M and CYP1A1*2A MspI with pathological symptoms of a rural population in south Greece. Xenobiotica 2011; 41:914-25.

Tschritter O, Stumvoll M, Machicao F et al. The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6. 2 (KIR6. 2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes 2002; 51:2854-60.

Tseng A, Macarthur RD. Profile of etravirine for the treatment of HIV infection. Ther Clin Risk Manag 2010; 6:49-58.

Tseng CH. Cardiovascular disease in arsenic-exposed subjects living in the arseniasis-hyperendemic areas in Taiwan. Atherosclerosis 2008; 199:12-8.

Tseng ZH, Aouizerat BE, Pawlikowska L et al. Common beta-adrenergic receptor polymorphisms are not associated with risk of sudden cardiac death in patients with coronary artery disease. Heart Rhythm 2008; 5:814-21.

Tseng-Crank J, Kost T, Goetz A et al. The alpha-1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Brit J Pharm 1995; 115:1475-85.

Tsimberidou AM, Lewis N, Reid T et al. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol 2011. doi:10. 1007/s00280-011-1635-7.

Tsimberidou AM, Takimoto CH, Moulder S et al. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther 2011; 10:209-17.

Tsimihodimos V, Elisaf M. Lipoprotein glomerulopathy. Curr Opin Lipidol 2011; 22:262-9.

Tsirulnikov K, Abuladze N, Koag MC et al. Transport of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, a metabolite of trichloroethylene, by mouse multidrug resistance associated protein 2 (Mrp2). Toxicol Appl Pharmacol 2010; 244:218-25.

Tsuang DW, Wilson RK, Lopez OL et al. Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology 2005; 64:509-13.

Tsuboi Y, Baker M, Hutton M et al. Clinical and genetic studies of families with the tau N279K mutation (FTDP-17). Neurology 2002; 59:1791-3.

Tsuchiya K, Gatanaga H, Tachikawa N et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319:1322-6.

Tsuchiya M, Katoh T, Motoyama H, Sasaki H, Tsugane S, Ikenoue T. Analysis of the AhR, ARNT, and AhRR gene polymorphisms: genetic contribution to endometriosis susceptibility and severity. Fertil Steril 2005; 84:454-8.

Tsuchiya M, Nakao H, Katoh T et al. Association between endometriosis and genetic polymorphisms of the estradiol-synthesizing enzyme genes HSD17B1 and CYP19. Hum Reprod 2005; 20:974-8.

Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005; 227:115-24.

Tsuji G, Takahara M, Uchi H et al. An environmental contaminant, benzo(a)pyrene, induces oxidative stress-mediated interleukin-8 production in human keratinocytes via the aryl hydrocarbon receptor signaling pathway. J Dermatol Sci 2011; 62:42-9.

Tsujimoto M, Dan Y, Hirata S, Ohtani H, Sawada Y. Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure. Drug Metab Pharmacokinet 2008; 23:406-11.

Tsujimoto M, Goto Y, Maruyama M, Hattori A. Biochemical and enzymatic properties of the M1 family of aminopeptidases involved in the regulation of blood pressure. Heart Fail Rev 2008; 13:285-91.

Tsujimoto M, Higuchi K, Shima D et al. Inhibitory effects of uraemic toxins 3-indoxyl sulfate and p-cresol on losartan metabolism in vitro. J Pharm Pharmacol 2010; 62:133-8.

Tsujimura S, Saito K, Nakayamada S, Tanaka Y. Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis. Mod Rheumatol 2010; 20:139-46.

Tsujioka H, Hachisuga T, Fukuoka M et al. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer. Int J Gynecol Cancer 2009; 19:1052-6.

Tsukada T, Tamaki K, Tanaka J et al. A prodrug approach towards the development of tricyclic-based FBPase inhibitors. Bioorg Med Chem Lett 2010; 20:2938-41.

Tsukahara M, Imaizumi K, Kawai S, Kajii T. Occipital horn syndrome: report of a patient and review of the literature. Clin Genet 1994; 45:32-5.

Tsukahara M, Yoshida A. Chromosomal assignment of the alcohol dehydrogenase cluster locus to human chromosome 4q21-23 by in situ hybridization. Genomics 1989; 4:218-20.

Tsukahara S, Ikari K, Sato E et al. A polymorphism in the gene encoding the Fcgamma IIIA receptor is a possible genetic marker to predict the primary response to infliximab in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67:1791-2.

Tsukahara S, Tsuda MC, Kurihara R et al. Effects of aromatase or estrogen receptor gene deletion on masculinization of the principal nucleus of the bed nucleus of the stria terminalis of mice. Neuroendocrinology 2011; 94:137-47.

Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa). Evid Based Complement Alternat Med 2005; 2:223-6.

Tsukamoto S, Aburatani M, Yoshida T, Yamashita Y, El-Beih AA, Ohta T. CYP3A4 inhibitors isolated from Licorice. Biol Pharm Bull 2005; 28:2000-2.

Tsukamoto S, Tomise K, Aburatani M et al. Isolation of cytochrome P450 inhibitors from strawberry fruit, Fragaria ananassa. J Nat Prod 2004; 67:1839-41.

Tsukamoto S, Tomise K, Miyakawa K et al. CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepper. Bioorg Med Chem 2002; 10:2981-5.

Tsunedomi R, Iizuka N, Hamamoto Y et al. Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol 2005; 27:661-7.

Tsunemi Y, Saeki H, Nakamura K et al. Interleukin-12 p40 gene (IL12B) 3’-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 2002; 30:161-6.

Tsunoda A, Nakao K, Watanabe M, Matsui N, Ooyama A, Kusano M. Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study. Ann Oncol 2011; 22:355-61.

Tsunoda SM, Harris RZ, Christians U et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001; 70:462-7.

Tsunoda SM, Harris RZ, Mroczkowski PJ, Benet LZ. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol 1998; 38:1137-43.

Tsunoka T, Kishi T, Ikeda M et al. Association analysis of Group II metabotropic glutamate receptor genes (GRM2 and GRM3) with mood disorders and fluvoxamine response in a Japanese population. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:875-9.

Tsutsumi A, Kanazawa T, Kikuyama H et al. Genetic polymorphisms in dopamine- and serotonin-related genes and treatment responses to risperidone and perospirone. Psychiatry Investig 2009; 6:222-5.

Tsutsumi Y, Kanamori H, Tanaka J, Asaka M, Imamura M, Masauzi N. Withdrawal symptoms from transdermal fentanyl (TDF) after an allogeneic peripheral blood stem cell transplant (PBSCT). Pain Med 2006; 7:164-5.

Tsuzaki K, Kotani K, Nagai N et al. Adiponectin gene single-nucleotide polymorphisms and treatment response to obesity. J Endocrinol Invest 2009; 32:395-400.

Tu HP, Ko AM, Wang SJ et al. Monoamine oxidase A gene polymorphisms and enzyme activity associated with risk of gout in Taiwan aborigines. Hum Genet 2010; 127:223-9.

Tu JH, Hu DL, Dai LL et al. Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Xenobiotica 2010; 40:393-9.

Tu Y, Cui G, Xu Y, Bao X, Wang X, Wang DW. Genetic polymorphism of CYP11B2 gene and stroke in the Han Chinese population and a meta-analysis. Pharmacogenet Genomics 2011; 21:115-20.

Tuckfield A, Clouston DR, Wilanowski TM, Zhao L-L, Cunningham JM, Jane SM. Binding of the RING Polycomb proteins to specific target genes in complex with the grainyhead-like family of developmental transcription factors. Molec Cell Biol 2002; 22:1936-46.

Tuerxun M, Hamulati W, Bai L, Peng XM, Dolikun M. Study of cytochrome P450 1A1 gene 3’-UTR 6235T-C polymorphism and susceptibility to breast cancer with Uighur medicine. Zhonghua Yi Xue Za Zhi 2011; 91:86-91.

Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK. Characterization of the human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem Biol Interact 1999; 118:171-89.

Tumer TB, Yilmaz D, Tanrikut C, Sahin G, Ulusoy G, Arinç E. DNA repair XRCC1 Arg399Gln polymorphism alone, and in combination with CYP2E1 polymorphisms significantly contribute to the risk of development of childhood acute lymphoblastic leukemia. Leuk Res 2010; 34:1275-81.

Tümer Z, Møller LB, Horn N. Mutation spectrum of ATP7A, the gene defective in Menkes disease. Adv Exp Med Biol 1999; 448:83-95.

Tumiatti V, Minarini A, Bolognesi ML, Milelli A, Rosini M, Melchiorre C. Tacrine derivatives and Alzheimer’s disease. Curr Med Chem 2010; 17:1825-38.

Tuminello ER, Han SD. The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis 2011. doi:10. 4061/2011/726197.

Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124:318-26.

Tuo J, Ning B, Bojanowski CM et al. Synergic effect of polymorphisms in ERCC6 5’ flanking region and complement factor H on age-related macular degeneration predisposition. Proc Natl Acad Sci USA 2006; 103:9256-61.

Tuohimaa P, Bläuer M, Pasanen S et al. Mechanisms of action of sex steroid hormones: basic concepts and clinical correlations. Maturitas 1996; 23:3-12.

Tuomainen AM, Hyvärinen K, Ehlers PI et al. The effect of proatherogenic microbes on macrophage cholesterol homeostasis in apoE-deficient mice. Microb Pathog 2011; 51:217-24.

Turley SD, Valasek MA, Repa JJ, Dietschy JM. Multiple mechanisms limit the accumulation of unesterified cholesterol in the small intestine of mice deficient in both ACAT2 and ABCA1. Am J Physiol Gastrointest Liver Physiol 2010; 299:1012-22.

Turner BA, Evans BP, Pearson TT, Braden TK, Wise SC. Examination of edge effects with different storage conditions of preplated dimethyl sulfoxide nanospots in ChemLib 1,536- and 3,456-well assay-ready plates. Assay Drug Dev Technol 2008; 6:811-8.

Turner NA, Doyle WA, Ventom AM, Bray RC. Properties of rabbit liver aldehyde oxidase and the relationship of the enzyme to xanthine oxidase and dehydrogenase. Eur J Biochem 1995; 232:646-57.

Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16:834-9.

Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001; 37:739-43.

Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. WNK1 kinase polymorphism and blood pressure response to a thiazide diuretic. Hypertension 2005; 46:758-65.

Turnes J, Hernández-Guerra M, Abraldes JG et al. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis. Hepatology 2006; 43:34-41.

Turolo S, Tirelli AS, Ferraresso M et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62:1159-69.

Turpeinen M, Hofmann U, Klein K, Mürdter T, Schwab M, Zanger UM. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes. Drug Metab Dispos 2009; 37:1017-24.

Turpeinen M, Korhonen LE, Tolonen A et al. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J Pharm Sci 2006; 29:130-8.

Turpeinen M, Nieminen R, Juntunen T, Taavitsainen P, Raunio H, Pelkonen O. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro. Drug Metab Dispos 2004; 32:626-31.

Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 2009; 23:748-53.

Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O. Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci 2005; 24:123-32.

Turriziani O, Pagnotti P, Pierangeli A et al. The effects of prolonged treatment with zidovudine, lamivudine, and abacavir on a T-lymphoblastoid cell line. AIDS Res Hum Retroviruses 2006; 22:960-7.

Tursen U, Kaya TI, Eskandari G et al. Apolipoprotein E gene polymorphism and serum lipids in patients with superficial fungal disease. Yonsei Med J 2004; 45:375-9.

Tushar T, Vinod T, Rajan S, Shashindran C, Adithan C. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers. Basic Clin Pharmacol Toxicol 2007; 100:269-72.

Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab 1997; 82:3777-82.

Tutuncu Z, Kavanaugh A, Zvaifler N, Corr M, Deutsch R, Boyle D. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum 2005; 52:2693-6.

Tuvesson H, Gunnarsson PO, Seidegård J. Metabolism of tauromustine in liver and lung microsomes from various species. Xenobiotica 1999; 29:783-92.

Tuvesson H, Hallin I, Persson R, Sparre B, Gunnarsson PO, Seidegård J. Cytochrome P450 3A4 is the major enzyme responsible for the metabolism of laquinimod, a novel immunomodulator. Drug Metab Dispos 2005; 33:866-72.

Tuvesson H, Wienkers LC, Gunnarsson PO, Seidegård J, Persson R. Identification of cytochrome P4503A as the major subfamily responsible for the metabolism of roquinimex in man. Xenobiotica 2000; 30:905-14.

Tüzüner BM, Oztürk T, Kisakesen HI et al. CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility. In Vivo 2010; 24:71-4.

Tvorogov D, Sundvall M, Kurppa K et al. Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. J Biol Chem 2009; 284:5582-91.

Twardowschy CA, Werneck LC, Scola RH, de Paola L, Silvado CE. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation. Arq Neuropsiquiatr 2011; 69:153-8.

Tweddell P, Boyle C. Potential interactions with herbal medications and midazolam. Dent Update 2009; 36:175-8.

Twine NA, Janitz K, Wilkins MR, Janitz M. Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer’s disease. PLoS One 2011. doi:10. 1371/journal. pone. 0016266.

Tyagi P, Tyagi V. Mirabegron, a β3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010; 13:713-22.

Tybring G, Böttiger Y, Widén J, Bertilsson L. Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997; 62:129-37.

Tyndale R, Aoyama T, Broly F et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991; 1:26-32.

Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7:375-9.

Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991; 31:655-60.

Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991; 40:63-8.

Tzaida O, Gogas H, Dafni U et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology 2007; 72:388-96.

Tzanakis N, Gazouli M, Rallis G et al. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 2006; 7:624-30.

Tzeng DS, Chien CC, Lung FW, Yang CY. MAOA gene polymorphisms and response to mirtazapine in major depression. Hum Psychopharmacol 2009; 24:293-300.

Tzourio C, El Amrani M, Poirier O, Nicaud V, Bousser MG, Alpérovitch A. Association between migraine and endothelin type A receptor (ETA -231 A/G) gene polymorphism. Neurology 2001; 56:1273-7.

Tzvetkov MV, Brockmöller J, Roots I, Kirchheiner J. Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment. Pharmacogenet Genomics 2008; 18:495-506.

Tzvetkov MV, Saadatmand AR, Bokelmann K, Meineke I, Kaiser R, Brockmöller J. Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J 2010. doi:10. 1038/tpj. 2010. 75.

Tzvetkov MV, Saadatmand AR, Lötsch J, Tegeder I, Stingl JC, Brockmöller J. Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther 2011; 90:143-50.